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Circulating tumour DNA (ctDNA) are short extracellular DNA fragments that have been 
explored by a number of studies to potentially reflect a more complete representation of 
tumour burden without utilizing the highly invasive tissue biopsy. Current advances in 
technology have investigated the use of multiplex droplet digital PCR (ddPCR) in 
providing a highly sensitive, simultaneous screening for multiple mutations in the ctDNA 
of limited clinical samples as an alternative to the current molecular detection approaches. 
This specific detection could potentially serve as a more accurate and cost-effective 
surveillance tool in clinical applications. Hence, the study was conducted in metastatic 
colorectal and breast cancer patients to investigate the use of multiplex ddPCR for the 
detection of tumour-specific mutations in ctDNA. Rare or difficult to detect pathogenic 
somatic mutations were identified for each cancer patient by sequencing their respective 
ctDNA and/or FFPE DNA. Patient samples were then subjected to an optimized 
multiplex ddPCR containing two gene mutation assays in a single ddPCR reaction. The 
assay was run on ctDNA isolated from several blood collection cycles of patients and the 
final mutant droplet concentration (copies per mL plasma ± SE) for each cycle was 
calculated.  
 
Dynamic serial changes in ctDNA were observed to correlate with disease burden, 
response to administered treatments and overall clinical outcome earlier than scheduled 
CT imaging. Higher levels of ctDNA were mostly observed in patients with metastasis to 
the liver compared to those with metastases to lymph nodes, lungs and bones.  Multiplex 
ddPCR assays also successfully detected KRAS, TP53, PIK3CA, BRCA2 and BRAF gene 
mutations in the ctDNA of metastatic breast and CRC patients. Similar dynamic patterns 
were observed for each mutation marker and the overall level of ctDNA is comparable to 
the results acquired from single mutation ddPCR assays. Overall, the results presented in 
this study have contributed to the establishment of the highly sensitive multiplex ddPCR 
analysis of ctDNA in serial blood samples as a possible cancer surveillance tool that 
could help combat the current limitations of the cancer healthcare system and hopefully 
reduce the continually increasing mortality rates of cancer in New Zealand. 
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CHAPTER 1: INTRODUCTION 
 
BACKGROUND 
Cancer is a genetic disease characterized by various mutations within the genome which 
disrupts the normal cellular functions thereby causing cells to over-proliferate and resist 
normal apoptotic signals (Fu et al., 2017; Tarazona et al., 2015). With approximately 11 
million cases of cancer every year, this malignancy is one of the leading causes of death in 
the world, fuelling the constant pursuit for more effective diagnosis methods and clinical 
techniques that may be used for optimal treatment and disease management of cancer (Bhatt, 
et al., 2010; Ma et al., 2015; Fu et al., 2017).  
 
In the recent years, there has been a steady increase in the cases of cancer in New Zealand, 
with the diagnosis of 23 000 new cancer cases per year and among the world‟s worst 
mortality rates according to the on-going Global Burden of Disease study (2016). This has 
ultimately made cancer the number one cause of death in the country. The study specifically 
focused on metastatic breast cancer and colorectal cancer, which will be discussed below.  
 
BREAST CANCER 
Specifically, breast cancer is the leading cause of cancer-related death in women worldwide 
(Turner et al., 2015; Ma et al., 2015) and New Zealand‟s third most commonly diagnosed 
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invasive malignancy which affects 3,300 women and 25 men each year and accounts for 
more than 600 annual deaths in New Zealand (Ministry of Health – Manatū Hauora, 2017). 
Breast cancer is a highly heterogeneous disease that has numerous risk factors, most 
commonly age and family history, and has an average 5-year relative survival rate for women 
of 90% (Seer Cancer Statistics Review, 2017). However, once the tumour has metastasized to 
distant parts of the body (i.e. lung, brain, bones and/or liver), it essentially becomes an 
incurable disease (5-year survival rate: 27%) which can only be treated with serial 
administration of systematic therapies, primarily based on histopathological features and 
molecular subtype of the tumour (Dawson et al., 2013; Olsson et al., 2015; Feng et al., 2018). 
 
COLORECTAL CANCER 
Colorectal cancer (CRC), on the other hand, is the second highest cause of mortality in both 
men and women in New Zealand. Moreover, with approximately 2800 new cases and around 
4 in 100 deaths each year, the country has become one of the highest colorectal cancer 
incidence and mortality rates in the world (Kidess-Sigal et al., 2016; L. Li et al., 2018; Ma et 
al., 2015). CRC is a highly complex disease which usually develops first as benign growths 
(most commonly referred to as polyps) in the lining of the colon and rectum. In several years, 
the aberrant cells inside the polyps may slowly develop into a tumour and consequently block 
the colon and rectum, thus affecting bowel function. Overall, the average 5-year relative 
survival rate for CRC is 64.6% (Seer Cancer Statistics Review, 2017), but the survival rates 
can vary based on the stage it was diagnosed. Once the heterogeneous malignancy has 
metastasised to distant parts of the body (most commonly in the liver or lungs), the survival 
rate drops down to 14%. Fortunately, colorectal cancer usually grows slowly over a number 
of years and can be treated successfully if detected and treated sufficiently early in the course 
of the disease (Li et al., 2019; Ministry of Health – Manatū Hauora, 2017). 
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The primary treatment for both colorectal and breast cancer mostly involves surgery to 
remove the tumour followed by adjuvant chemotherapy or radiation therapy (Ma et al., 2015; 
Fu et al., 2017; Li et al., 2019). However, with the evidently persistent high mortality and 
incidence of these cancers in New Zealand (Global Burden of Disease study, 2016) and the 
limited treatments available for stages of both types of cancer (Ministry of Health – Manatū 
Hauora, 2017), it is clear that establishing an accurate and effective disease progression 
monitoring tool for colorectal and breast cancer would help achieve better patient prognosis 
and increased survival rates (Ma et al., 2015; Shao et al., 2016).  
 
TUMOUR-SPECIFIC MUTATIONS 
The analysis of tumour-specific mutations may be used as a basis of understanding aberrant 
tumour cell proliferation and potentially establish the origin of cancer in an individual (Choi 
et al., 2017). Numerous studies have focused on the detection of rare tumour-specific 
mutations in several types of cancer as novel cancer biomarkers for the diagnosis, prognosis 
and surveillance of tumour burden (Olmedillas-López et al., 2017; Christensen et al., 2018; 
Taly et al., 2013).  
 
Since the development of cancer involves the continuous acquisition of new mutations, it is 
essential to monitor somatic mutations as these occur at low variant allelic fractions with a 
negligible rate on normal cell population. Thus, these can thereby provide an excellent 
representation of the disease (Ma et al., 2015; Fredslund & Jakobsen, 2016).  
 
However, the screening of these relevant mutations in circulation is very challenging, 
especially in localized tumours and early stages of malignancy or recurrence. The difficulty 
in detecting these rare mutations therefore presents the need for an extremely sensitive 
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technique that can differentiate a specific mutant sequence variant present at a very low 
frequency in a pool of a highly similar wild type background (Olmedillas-López et al., 2017; 
Christensen et al., 2018; El-Heliebi & Heitzeer, 2019). 
 
TUMOUR TISSUE ANALYSIS 
Cancer patients usually undergo genetic analysis of archived tumour tissues from the biopsy 
or resection of primary tumours for the detection of specific mutations that may guide the 
appropriate treatment (Fu et al., 2017; Kidess-Sigal et al., 2016). However this approach has 
a very significant disadvantage since direct tumour tissue analysis may not provide a 
complete representation of tumour heterogeneity,  specifically in breast cancer patients who 
usually have a huge time delay between the standard resection and later relapse requiring 
chemotherapy (Li et al., 2019; Jackson et al., 2016),  
 
Furthermore, the DNA extracted from the formalin-fixed paraffin-embedded (FFPE) tumour 
blocks is often prone to degradation over time, essentially leading to poor sample quality and 
higher frequency of assay failures. A high degree of optimization is usually required to 
minimise test failures when using archived FFPE DNA for molecular analysis (Olmedillas-
López et al., 2017; So et al., 2018; Wyatt, et al., 2018; Taly et al., 2013). In addition, since 
genomic alterations evolve in primary and metastatic tumour tissues, appropriate 
management of the disease would require serial tissue biopsies (Tarazona et al., 2015; 
Olmedillas-López et al., 2017).  
 
However, due to the cost, invasiveness and technical difficulty of this technique, serial 
biopsies are rarely possible (Kidess-Sigal et al., 2016; Ma et al., 2015). In order to improve 
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the current approach, this study explored novel non-invasive methods that can provide a more 
reliable representation of the tumour dynamics, especially in cases of advanced malignancy. 
 
CIRCULATING TUMOUR DNA 
Currently, there has been focus on studies regarding the use of liquid biopsies through 
circulating tumour DNA (ctDNA) as a feasible alternative in providing a real-time 
assessment of tumour-specific mutations in patients (Calapre et al., 2017; Li et al., 2019). 
These are short tumour-derived cell-free DNA fragments (approximately 160bp long), found 
in bodily fluids (plasma or serum), which may be used as a potential source for the 
characterization of the somatic, genomic and epigenetic aberrations of tumours (Labgaa et al., 
2018; Turner et al., 2015).  
 
ctDNA is released into the bloodstream as a result of cancer cell apoptosis, necrosis, and 
exocytosis (Figure 1.1), with its presence generally reflecting the complete tumour burden in 
cancer patients, often more accurately than comparable protein markers (Kidess-Sigal et al., 
2016; Tjensvoll et al., 2015).   
 
 
Figure 1.1. Graphical representation circulating tumour DNA released into the bloodstream 




Clinical value of ctDNA 
The analysis of ctDNA can offer evident clinical advantages over tumour analysis by 
providing a more complete and unbiased representation of tumour heterogeneity and by 
providing diagnostic and prognostic information before, during treatment and at progression 
with only a small quantity of blood (Mao et al., 2017; Tjensvoll et al., 2015). This faster and 
cost-effective alternative approach can be more frequently done and easily repeated with 
minimal risk to the cancer patient. ctDNA may be utilized for the detection and more accurate 
surveillance of mutations that can be targets for personalized drug therapies (Ni et al., 2017; 
Labgaa et al., 2018) and it may also serve as a predictive biomarker for the early detection of 
cancer recurrence before it becomes clinically detectable (Fredslund & Jakobsen, 2016; 
Christensen et al., 2018; Taly et al., 2013). Furthermore, since ctDNA arises from the 
apoptosis of any tumour cell, it may be used to monitor the likely increase in the population 
of new mutations or the emergence of acquired resistant clones which may have been initially 
present in the cancer at a low frequency, but may have possibly amplified upon the extrinsic 
influences of targeted drug therapy (Taly et al., 2013). 
 
Challenges when dealing with ctDNA 
Detection of ctDNA relies upon the identification of mutations that generally reflect the 
complete tumour burden (Calapre et al., 2017). However, only an extremely small fraction of 
cell-free DNA fragments found in plasma originates from tumour cells (Jackson et al., 2016; 
Christensen et al., 2018) and thus, tumour-specific genomic alterations present in ctDNA may 
only be detected in low frequencies (1-10 ng/mL). As a result, detection of ctDNA in patient 
samples requires the use of extremely sensitive and specific techniques as there is still a need 
to differentiate rare mutant ctDNA copies from the wild type cell-free DNA fragments, which 
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are also generally present in plasma as a result of usual cell turn-over (Kidess-Sigal et al., 
2016; Mao et al., 2017). 
 
Current techniques for the detection of ctDNA 
There are several methodological approaches that have been applied to the detection of 
ctDNA. In most studies, tumour-specific mutations are identified using polymerase chain 
reaction (PCR)-based methods (Wyatt et al., 2018). However, since ctDNA is present at 
levels as low as <0.01% of total circulating DNA, especially in residual disease or during the 
early stages of cancer, the use of conventional qPCR-based methods, which offers 
sensitivities of 10-20%, would be impractical as it could not demonstrate enough analytical 
sensitivity (Taly et al., 2013; Alcaide et al., 2016).  
 
Current approaches involve the use of other PCR-based methods such as BEAMing (beads, 
emulsion, amplification and magnetics) and droplet digital PCR (ddPCR), which both utilizes 
water-in-oil droplets for the amplification and quantification of DNA. These methods offer a 
significant advantage over the conventional qPCR approach since BEAMing and ddPCR 
allow for the detection of low frequency mutations with limits up to 0.01% and 0.001% 
respectively (Calapre et al., 2017; Tjensvoll et al., 2015). Hence, even with minimal amounts 
of starting plasma material, a more efficient amplification of DNA with lower false positive 
rates can be observed in BEAMing and ddPCR, as compared to conventional standard 
techniques (Taly et al., 2013; Wyatt et al., 2018).  
 
However, in order for a screening method to be used for clinical applications, not only should 
it provide analysis with very high sensitivity but it must also be quick and cost-effective, with 
little methodological variability between experiments. Currently, the superior method with 
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the highest sensitivity and accuracy which meets all these conditions and one of the most 
widely used techniques for clinical ctDNA analysis is ddPCR (Taly et al., 2013; Deng et al., 
2018; Fredslund & Jakobsen, 2016).  
 
DROPLET DIGITAL PCR 
ddPCR is a highly sensitive, standard probe-based technique which enables the 
compartmentalization of DNA into thousands of droplets through a water-in-oil emulsion 
(Jackson et al., 2016; Olmedillas-López et al., 2017), thereby reducing the number of target 
DNA molecules to either only a single copy or no copies at all per independent PCR reaction 
represented in each partitioned droplet (Figure 1.2). As a result, ddPCR allow for the 
effective detection and increased allelic discrimination of low frequency mutations by the 
parallel amplification of thousands of ctDNA fragments found in patient samples (Taly et al., 
2013; Alcaide et al., 2016).  
 
 
Figure 1.2. A sample ddPCR sample partitioned into droplets (Droplet DigitalTM PCR 
Application Guide) 
 
Moreover, since quantification in ddPCR is done based upon the number of mutant droplets 
with positive fluorescent signals rather than cycle thresholds which is utilized in conventional 
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PCR methods, there is a lower probability of error. The results that can be obtained would 
ultimately be more accurate and reproducible in reference to other standard techniques such 
as FISH and IHC, since ddPCR has a simpler, more automated and less subjective protocol 
that can easily be adapted in any laboratory (Olmedillas-López et al., 2017). However, while 
ddPCR could offer excellent sensitivity and specificity for the detection and absolute 
quantification of ctDNA for research applications (Deng et al., 2018; Taly et al., 2013), this 
method still requires the prior identification of relevant tumour-specific mutations that could 
be targeted for analysis (Christensen et al., 2018). 
 
TARGETED NEXT GENERATION SEQUENCING 
Targeted next generations sequencing (NGS) of pre-determined gene panels is currently 
being adapted for the fast and highly sensitive identification of a large number of key somatic 
driver mutations and recurrent genetic aberrations in individual cancer patient samples that 
may have implications for treatment and prognosis, and could optimally be targeted for 
analysis (So et al., 2018; L. Li et al., 2018; Wyatt et al., 2018). This procedure has 
contributed to the fundamental understanding of the numerous molecular processes that 
contribute to cancer development (Christensen et al., 2018). 
 
Targeted NGS of ctDNA can provide a more sensitive method of detection for genetic 
alterations in sequenced ctDNA samples with effectively lower error rates. The library 
preparation for targeted NGS incorporates unique molecular identifiers (UMIs) or barcodes 
prior to amplification in order to reveal even the considerably highly „diluted‟ mutations 
across the entire genome. With the addition of UMIs (Figure 1.3), the raw reads can be 
grouped by identical UMIs which originated from the same DNA fragment to thereby create 
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unique high-confidence reads that mimic the original DNA fragments (Schwaederlé et al., 
2017; Calapre et al., 2017; Christensen et al., 2018; Wyatt et al., 2018). 
 
 
Figure 1.3. Principle of variant detection with UMIs (QIAseqTM Targeted DNA Panel 
Handbook, 2017) 
 
Since targeted NGS of ctDNA with UMIs require high sequencing depth coverage, the cost 
of this technique may rapidly escalate if performed beyond a few genomic targets and 
frequent repeats of targeted NGS for every plasma sample from patients may be labour-
intensive and impractical for developing a cost-effective cancer surveillance tool (Wyatt et 
al., 2018; So et al., 2018; Fredslund & Jakobsen, 2016). Therefore, the high throughput and 
comprehensive targeted NGS could be utilized in combination with the highly sensitive and 






MULTIPLEX DDPCR ASSAY 
However, due to tumour heterogeneity, the evaluation of a single gene mutation target in 
ctDNA analysis may not be enough to provide a comprehensive analysis of the cancer 
genome It would be optimal to simultaneously monitor multiple mutation markers using 
multiplex ddPCR assays in order to obtain the most information from a limited amount of 
available ctDNA samples (Olmedillas-López et al., 2017; Ma et al., 2015; Taly et al., 2013).  
Not only will this approach enable potentially more accurate and cost-effective tests for 
monitoring disease relapse and patients‟ response to treatment, but it may evaluate the 
possible clonal evolution that occurs in response to therapies with higher sensitivity in 




This study focused on the Hauora/Oranga theme, specifically for the improvement of Health 
and Social Well-being of Māori communities. Breast cancer is the most common cancer and 
the second leading cause of cancer death registered for Māori females. The breast cancer 
registration rate for Māori females is 1.4 times that of non-Māori females, while the mortality 
rate of breast cancer in Māori females is 1.5 times that of non-Māori females possibly since 
they have less access to mammography screening tests and tend to only seek medical 
attention at a more advanced stage of the disease. Colorectal cancer registration rates, on the 
other hand, were significantly lower for Māori than for non-Māori but there was no 
significant difference between their mortality rates (Dachs et al., 2008; Ministry of Health – 




With the evident increase in the clinical relevance of ctDNA, developing a multiplex ddPCR 
assay for the detection of tumour-specific mutations in ctDNA may help provide a more 
reliable and non-invasive surveillance tool to potentially evaluate patients' response to 
treatment and monitor disease progression or recurrence with just a simple routine blood test.  
In contrast to tumour tissue biopsies, blood samples can easily be collected and then shipped 
anywhere within the country.  
 
Specifically, the study will enable better cancer care of Maori communities by enabling better 
cancer surveillance to be initiated in marae health clinics and even in rural areas that are 
geographically isolated from large hospital facilities. Ultimately, establishment of this 
multiplex ddPCR assay could potentially help combat the current limitations of the cancer 




Here, we describe a method for the substantial optimization of multiplex ddPCR assays for 
the simultaneous detection of two tumour-specific mutations in ctDNA extracted from serial 
plasma and FFPE tumour tissue samples of metastatic colorectal and breast cancer patients. 
Specifically, this study aims: 
1. To sequence and detect tumour-specific mutations in the FFPE  DNA and ctDNA 
extracted from clinical samples of metastatic breast cancer patients;  
2. To design and optimize assays for the multiplex ddPCR of FFPE DNA and ctDNA 
extracted from clinical samples of metastatic breast cancer patients; and 
3. To optimize assays for the multiplex ddPCR of FFPE DNA and ctDNA extracted 




The study was divided into two parts. In Chapter 3, circulating tumour DNA was first 
investigated as a highly sensitive biomarker to potentially provide an accurate measure of the 
tumour burden in 34 women from Dunedin and Auckland, New Zealand undergoing systemic 
therapy for metastatic breast cancer. Upon the identification of tumour-specific mutations 
prevalent in the FFPE and ctDNA samples using Targeted NGS, the study was limited to 
designing personalized ddPCR assays for the subsequent ctDNA analysis of serial plasma 
samples collected prior each chemotherapy cycle.  
 
In Chapter 4, the potential of multiplex ddPCR for the concurrent monitoring of multiple 
mutations was then explored as a part of a larger Colorectal Cancer Project funded by 
Healthier Lives. The study was limited to the optimization of multiplex ddPCR assays in the 
FFPE DNA of seven advanced CRC patients from New Zealand. Once the multiplex ddPCR 
assays were successfully optimized for each patient, the study then focused on the 
surveillance of two somatic mutation markers in the limited volumes of ctDNA isolated from 















CHAPTER 2: METHODOLOGY 
 
ETHICAL APPROVAL OF PATIENT SAMPLES 
Ethical approval for the pilot study of ctDNA analysis in metastatic CRC patients was 
obtained from the Ministry of Health; Health and Disability Ethic Committee (reference 
number 16/STH/158), while the ethical approval for the ctDNA analysis in metastatic breast 
cancer patients was obtained from the New Zealand Multi - Region Ethics Committee 
(reference number MEC/09/06/060). Patients were recruited from two study locations within 
New Zealand; Auckland (Dr. Annette Lasham, University of Auckland) and Dunedin 
(Professor Parry Guilford, University of Otago). The consent for the use of FFPE tumour 
block tissue and the collection of blood samples from patients who had undergone surgical 
removal of their primary tumour and were receiving chemotherapy treatment was obtained by 
their respective oncology departments.  
 
FFPE DNA IN PATIENT SAMPLES 
Tumour Tissue Micro-sectioning 
Tumour blocks from colorectal cancer and breast cancer patients were sectioned into 5µM 
and 10µm using a Leica RM 2125RT Sectioner [BioStrategy, New Zealand]. The obtained 
tumour tissue sections were then placed in a Leica HI1210 Water Bath [Bio-Strategy, New 
Zealand] at 40oC for 30-60 seconds to disperse the tissue before it was mounted onto a 
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microscope glass slide [Marienfeld, Germany]. The slides were dried in an oven [Contherm 
Thermotec 2000 Oven, Contherm Scientific Ltd, New Zealand] at 55oC for 3 hours and then 
stored in a microscope slide box at room temperature until further use.  
 
FFPE DNA Extraction 
In order to differentiate cancerous tissue from normal tissue in the prepared FFPE tumour 
tissue sections, 5µM sample slides were stained with Mayer‟s Haematoxylin Solution [Sigma 
Aldrich, USA ref. MH532] and Eosin Y Solution [Sigma Aldrich, USA ref. HT110116] in a 
Fume Cupboard 326h [Thermoplastic Engineering Ltd, New 51 Zealand]. The cancerous part 
of the tissue sections was carefully scraped off from ideally 2-3 10µM slides per tumour 
block and transferred into a collection tube. The FFPE DNA was then extracted using the 
Qiagen GeneRead DNA FFPE Kit [Qiagen, Germany ref. QIA180134] as per the 
manufacturer‟s protocol. The given protocol was however optimized by the elution of the 
final DNA in 30µL of UltraPure DNAse/RNAse Free Distilled Water [Thermo Fischer 
Scientific, USA ref. 1097715] instead of the provided ATE Buffer.  
 
FFPE DNA Fragmentation and Quantification 
The samples were subjected to fragmentation to 350bp through the Covaris S220 Focused-
ultrasonicator [Covaris, USA] and the concentration of the eluted FFPE DNA was then 
measured using the Qubit 2.0 Fluorometer with dsDNA High Sensitivity Kit [Thermo Fischer 
Scientific, USA ref. Q32854] as per the manufacturer‟s protocol. The final FFPE DNA 
concentration (ng/µL) was then calculated using the following formula.  
 
                                
              ⁄             





If the obtained FFPE DNA had a concentration of less than 5ng/µL, then the sectioning and 
staining process was repeated to ensure that there is sufficient DNA for the subsequent 
ddPCR procedure. The obtained ctDNA samples were then stored in -80oC until further use. 
 
CIRCULATING TUMOUR DNA IN PATIENT SAMPLES 
Blood Sample Collection 
Ten millilitres of blood were drawn from cancer patients immediately prior to their 
chemotherapy treatment by venipuncture into 5X Cell Free DNA Blood Collection Tubes® 
[Roche, Switzerland ref. 778566601] by a registered nurse or phlebotomist. The blood 
samples were then brought to the Cancer Genetics Laboratory [Department of Biochemistry, 
University of Otago, Dunedin, New Zealand] and stored upright in a test tube rack at 22oC 
until the maximum delay time of seven days for sample processing.  
 
Plasma Separation from blood samples 
The blood samples were subjected to centrifugation [Eppendorf Centrifuge 5810R] first at 
200 rcf, and then at 1600 rcf for 10 minute intervals with both break and acceleration set at 
zero. The plasma was then separated from the red blood cells (RBC) and transferred into 
15mL centrifuge tubes [Griener Bio-one, Austria] and spun again at 1600 rcf to remove cell 
debris and intact white blood cells. The plasma samples were then transferred to 5mL 
Eppendorf tubes and stored in -80oC until further use. 
 
ctDNA Extraction 
The cell free DNA was then extracted from the obtained plasma using the QIAmp Circulating 
Nucleic Acid Kit [Qiagen, USA ref. QIA5514] as per the manufacturer‟s protocol for 4mL of 
plasma. The given protocol was however optimized by the elution of the final DNA in 52µL 
17 
 
of UltraPure DNAse/RNAse Free Distilled Water [Thermo Fischer Scientific, USA ref. 
1097715] instead of the provided Buffer AVE. The obtained ctDNA samples were then 
stored in -80oC until further use. 
 
NEXT GENERATION SEQUENCING OF PATIENT SAMPLES 
CRC patient samples were all previously sequenced in the pilot study of ctDNA in CRC and 
the tumour specific mutations for each individual patient were also previously identified in 
our laboratory. Tumour-specific mutations for breast cancer patient samples, on the other 
hand, were identified and sequenced as follows. 
 
Library Preparation & Target Enrichment 
Sequencing libraries for breast cancer patient samples were first prepared by diluting the 
ctDNA and/or FFPE DNA samples to 5ng/µL with a final working volume of 16µL. 
Capillary electrophoresis analysis was then done on 1µL of sample using the Agilent 2100 
Bioanalyzer with the High Sensitivity DNA analysis kit. The remaining 15µL of samples 
were then mechanically sheared to approximately 200bp using the Covaris S220 Focused-
ultrasonicator [Covaris, USA]. The QIAseq Targeted DNA Panel (Human Breast Cancer) 
[Qiagen, Germany ref. DHS-001Z] was used for sample library construction and target 
enrichment of around 75-100ng of ctDNA or FFPE DNA as per the manufacturer‟s protocol 
(Figure 2.1). The time for the fragmentation, end-repair and A-addition step at 32°C was 





Figure 2.1. QIAseqTM Targeted DNA Panel workflow (2017). 
 
Sequencing of patient samples 
The libraries were quantified using the Qubit 2.0 Fluorometer with the dsDNA High 
Sensitivity Kit [Thermo Fischer Scientific, USA ref. Q32854] and subjected to Bioanalyzer 
[Agilent Technologies, USA] analysis. Around 4-6 generated patient libraries are then 
combined to get a total of 4nM. Five microliters (5µL) of the combined libraries were then 
added to 5µL of 0.2M sodium hydroxide (NaOH) and vortexed briefly before leaving it at 
room temperature for 5mins. A final stock concentration of 20pM was prepared by adding 
990µL of Hybridization Buffer [Illumina, USA] and the denatured libraries. Then, 8pM of 
the library mix was then loaded into a MiSeq v2 reagent cartridge and run on the Illumina 
MiSeq platform [Illumina, USA] for a total of 316 cycles of sequencing. 
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An output “.fastq” was generated and downloaded from the Illumina Basespace Sequence 
Hub and uploaded to the QIAGEN QIASeq DNA Enrichment Portal 
(https://ngsdataanalysis.qiagen.com/QIAseqDNA/). DHS-001Z (Breast Cancer) was selected 
for the QIASeq DNA Catalogue Number and all the breast cancer read files were selected. 
Jobs were then created for all the breast cancer samples and on successful completion; the 
“Output Archive” was downloaded and opened using Microsoft Excel.  
 
Pathogenic Mutation Identification 
All mutation data were sorted for each individual patient and passed with all the variant 
calling filters. The variant mutation frequency (VMF) of each mutation data was then sorted 
from highest (1.0) to lowest (0.0). Mutations with VMF within the range 0.1-0.45 or 0.6-0.85 
were chosen, while mutations within the range 0.46-0.55 or 0.95-1.00 were disregarded since 
these are highly likely to be heterozygous or homozygous germline mutations.  
 
Previously published information regarding each selected mutation was then analysed using 
COSMIC (https://cancer.sanger.ac.uk/cosmic) and Varsome (https://varsome.com/) databases 
using the COSMIC number or reference SNPs (rs) ID number. Only the mutations found in 
breast cancer that are pathogenic in both COSMIC (FATHMM>0.90) and Varsome; and 
made up a very small proportion of the general population (i.e. <0.0001) were selected for 
further analysis.  
 
MULTIPLEX DDPCR ASSAY FOR CANCER PATIENTS 
Design of Primer and Probes 
Primers and probes for tumour-specific mutations identified for CRC patient samples (Table 
2.1) were all previously designed, while novel primers and probes for tumour-specific 
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mutations identified for breast cancer patient samples (Table 2.2) were designed using 
Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) following 
the parameters as optimal for RED assay design, as recommended by Bio-Rad. The product 
range was set to 60-100bp long with the forward and reverse primer size opted to range from 
15-36bp and the optimal length set to 20bp to improve quantification. The melting 
temperature of the primers were set between the range of 50-65oC with the optimal 
temperature set to 60oC, and at least one G or C was added within the 3‟ end and if possible, 
also on the 5‟ end. The thermodynamic parameters and salt correction formula were both as 
per SantaLucia (1998).  
 
The length of the probes was limited to 15-27 bp with 20 bp being the optimal length to 
prevent cross-reactivity. Probes were designed to have more Cs than Gs and were made sure 
not to have a G in the 5‟ end to avoid fluorophore quenching. The melting temperature was 
set between 62oC to 70oC with the optimal temperature at 63oC. The concentration of divalent 
cations and dNTPs was set to 3.8nM and 0.8nM respectively for both the primers and probes.  
 
The specificity of forward and reverse primer design was then subsequently checked with the 
NCBI PrimerBlast software. The primer and probes were then synthesized by Integrated 
DNA Technologies, USA at a stock concentration of 100 nM and diluted to a working 
concentration of 20 nM upon arrival.  Probes were ordered with the reporter fluorophores 
dyes FAM (mutant) and HEX (wild type) along with the double quencher ZEN™ and the 3‟ 






Table 2.1. Primer and probe sequences for tumour-specific mutations in CRC patients 
MUTATIONS  SEQUENCE 
APC c.3203 C>G Forward Primer 5‟- GCAAGACCCAAACACATA -3‟ 
Reverse Primer 5‟- GCTCTCAGTATAAACAGGAT -3‟ 
Mutant type Probe 5‟- /6-FAM/ AGCAAAGAC/ZEN/AATGAAGGAATC /IABkFQ/ -3‟ 
Wild type Probe 5‟- /HEX/ AGCAAAGAC/ZEN/AATCAAGGAATC /IABkFQ/ -3‟ 
BRAF c.1799T>A Forward Primer 5‟- TCATGAAGACCTCACAGTAA -3‟ 
 Reverse Primer 5‟- CTGTTCAAACTGATGGGAC -3‟ 
 Mutant type Probe 5‟- /6-FAM/ TGGTCTAGC/ZEN/TACAGAGAAATCTC /IABkFQ/ -3‟ 
 Wild type Probe 5‟- /HEX/ TGGTCTAGC/ZEN/TACAGTGAAATCTC /IABkFQ/ -3‟ 
KRAS c.35 G>A Forward Primer 5‟- AAGGCCTGCTGAAAATGACT -3‟ 
Reverse Primer 5‟- TAGCTGTATCGTCAAGGCAC -3‟ 
Mutant type Probe 5‟- /6-FAM/ TAGTTGGAG/ZEN/CTGATGGCGTAGG /IABkFQ/ -3‟ 
Wild type Probe 5‟- /HEX/ TAGTTGGAG/ZEN/CTGGTGGCGTAG /IABkFQ/ -3‟ 
KRAS c.35 G>T Forward Primer 5‟- AAGGCCTGCTGAAAATGACT -3‟ 
Reverse Primer 5‟- TAGCTGTATCGTCAAGGCAC -3‟ 
Mutant type Probe 5‟- /6-FAM/ TAGTTGGAG/ZEN/CTGTTGGCGTAGG /IABkFQ/ -3‟ 
Wild type Probe 5‟- /HEX/ TAGTTGGAG/ZEN/CTGGTGGCGTAG /IABkFQ/ -3‟ 
TP53 c.524 G>A Forward Primer 5‟- ATCTACAAGCAGTCACAGCA -3‟ 
Reverse Primer 5‟- TCACCATCGCTATCTGAGC -3‟ 
Mutant type Probe 5‟- /6-FAM/ AGGTTGTGA/ZEN/GGCACTGCC /IABkFQ/ -3‟ 
Wild type Probe 5‟- /HEX/ AGGTTGTGA/ZEN/GGCGCTGC /IABkFQ/ -3‟ 
TP53 c.794 T>A Forward Primer 5‟- TTGCTTCTCTTTTCCTATCC -3‟ 
Reverse Primer 5‟- AAACACGCACCTCAAAG -3‟ 
Mutant type Probe 5‟- /6-FAM/ ATCTACAGG/ZEN/GACGGAACA /IABkFQ/ -3‟ 
Wild type Probe 5‟- /HEX/ ATCTACTGG/ZEN/GACGGAACA /IABkFQ/ -3‟ 
TP53 c.817 C>T Forward Primer 5‟- TAGTGGTAATCTACTGGGAC -3‟ 
Reverse Primer 5‟- GGAGATTCTCTTCCTCTGT -3‟ 
Mutant type Probe 5‟- /6-FAM/ CTTTGAGGT/ZEN/GTGTGTTTGTG /IABkFQ/ -3‟ 
Wild type Probe 5‟- /HEX/ CTTTGAGGT/ZEN/GCGTGTTTG /IABkFQ/ -3‟ 
TP53 c.818 G>A Forward Primer 5‟- TAGTGGTAATCTACTGGGAC -3‟ 
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Reverse Primer 5‟- GGAGATTCTCTTCCTCTGT -3‟ 
Mutant type Probe 5‟- /6-FAM/ CTTTGAGGT/ZEN/GCATGTTTGT /IABkFQ/ -3‟ 
Wild type Probe 5‟- /HEX/ CTTTGAGGT/ZEN/GCGTGTTTG /IABkFQ/ -3‟ 
 
Table 2.2. Primer and probe sequences for tumour-specific mutations in BRC patients 
MUTATIONS  SEQUENCE 
CDH1 c1171delG Forward Primer 5‟- AATGACACATCTCTTTGCTC -3‟ 
 Reverse Primer 5‟- ATCAGCATCAGTCACTTTC -3‟ 
 Mutant type Probe 5‟-/6-FAM/AACGAGGCT/ZEN/AACTCGTAATC/IABkFQ/ -3‟ 
 Wild type Probe 5‟-/HEX/AGGCTAACG/ZEN/TCGTAATCAC /IABkFQ/ -3‟ 
BRCA1 c.349_350delCA Forward Primer 5‟- CCCATACTTTGGATGATAG -3‟ 
 Reverse Primer 5‟- ACAGATGCAAACAGCTA -3‟ 
 Mutant type Probe 5‟-/6-FAM/ATCTTTTAG/ZEN/ATTCAGGAGAGTT /IABkFQ/ -3‟ 
 Wild type Probe 5‟-/HEX/ATCTTTTAG/ZEN/ATGTTCAGGAGA/IABkFQ/ -3‟ 
BRCA2 c.8049delA 
 
Forward Primer 5‟- AGAAGCAGAAGATCGGCTAT -3‟ 
Reverse Primer 5‟- CGCTCAATGAAATTATGTCAGA -3‟ 
Mutant type Probe 5‟-/6-FAM/ACACAGCTG/ZEN/CAAAACACTTG/IABkFQ/ -3‟ 
Wild type Probe 5‟-/HEX/ACACAGCTG/ZEN/CAAAAACACTT/IABkFQ/ -3‟ 
ESR1 c.1636G>A Forward Primer 5‟- GTACAGCATGAAGTGCAAGA -3‟ 
 Reverse Primer 5‟- TAGTGGGCGCATGTAGG -3‟ 
 Mutant type Probe 5‟- /56-FAM/AGATGCTGG/ZEN/ACACCCACC/3IABkFQ/ -3‟ 
 Wild type Probe 5‟- /5HEX/AGATGCTGG/ZEN/ACGCCCACC/3IABkFQ/ -3‟ 
KRAS c.35 G>T Forward Primer 5‟- AAGGCCTGCTGAAAATGACT -3‟ 
Reverse Primer 5‟- TAGCTGTATCGTCAAGGCAC -3‟ 
Mutant type Probe 5‟- /6-FAM/ TAGTTGGAG/ZEN/CTGTTGGCGTAGG /IABkFQ/ -3‟ 
Wild type Probe 5‟- /HEX/ TAGTTGGAG/ZEN/CTGGTGGCGTAG /IABkFQ/ -3‟ 
PIK3CA c.1034A>G Forward Primer 5‟- CCCTTTGGGTTATAAATAGTGC -3‟ 
Reverse Primer 5‟- GCATCAGCATTTGACTTTACC -3‟ 
Mutant type Probe 5‟- /56-FAM/ TGCAACCTA/ZEN/CGTGAGTGTAA/3IABkFQ/ -3‟ 
Wild type Probe 5‟- /5HEX/TGTGCAACC/ZEN/TACGTGAATGT/3IABkFQ/ -3‟ 
PIK3CA c.1624G>A Forward Primer 5‟- CTCAAAGCAATTTCTACACG -3‟ 
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Reverse Primer 5‟- TTACCTGTGACTCCATAGAA -3‟ 
Mutant type Probe 5‟- /56-FAM/CCTCTCTCT/ZEN/AAAATCACTGAGC/3IABkFQ/ -3‟ 
Wild type Probe 5‟- /5HEX/CTCTCTCTG/ZEN/AAATCACTGAGC/3IABkFQ/ -3‟ 
PIK3CA c.1633G>A Forward Primer 5‟- TGACAAAGAACAGCTCAAAGC -3‟ 
Reverse Primer 5‟- AGCACTTACCTGTGACTCCA -3‟ 
Mutant type Probe 5‟-/6-FAM/CCTCTCTCT/ZEN /GAAATCACTAAGCAGG/IABkFQ/-3‟ 
Wild type Probe 5‟-/HEX/TCTCTGAAA/ZEN/ TCACTGAGCAGGAGA/IABkFQ/-3‟ 
PIK3CA c.3140A>G 
 
Forward Primer 5‟- ATAAAACTGAGCAAGAGGCT -3‟ 
Reverse Primer 5‟- GTGTGGAAGATCCAATCCAT -3‟ 
Mutant type Probe 5‟- /56-FAM/TGAATGATG/ZEN/CACGTCATGGT/3IABkFQ/-3‟ 
Wild type Probe 5‟- /5HEX/TGAATGATG/ZEN/CACATCATGGTG/3IABkFQ/ -3‟ 
TP53 c.288_289insA Forward Primer 5‟- CTGCCCTGGTAGGTTT -3‟ 
Reverse Primer 5‟- ACCAGCAGCTCCTAC -3‟ 
Mutant type Probe 5‟- /6-FAM/AAGGGACTA/ZEN/GAAGATGACAG/3IABkFQ/ -3‟ 
Wild type Probe 5‟- /HEX/AAGGGACAG/ZEN/AAGATGACAG/3IABkFQ/ -3‟ 
TP53 c.524G>A 
 
Forward Primer 5‟- ATCTACAAGCAGTCACAGCA -3‟ 
Reverse Primer 5‟- TCACCATCGCTATCTGAGC -3‟ 
Mutant type Probe 5‟- /6-FAM/ AGGTTGTGA/ZEN/GGCACTGCC /IABkFQ/ -3‟ 
Wild type Probe 5‟- /HEX/ AGGTTGTGA/ZEN/GGCGCTGC /IABkFQ/ -3‟ 
TP53 c.560-1G>A Forward Primer 5‟- GCCTCTGATTCCTCACTGAT-3‟ 
Reverse Primer 5‟- TCCACTCGGATAAGATGCTG -3‟ 
Mutant type Probe 5‟- /56-FAM/TCTTAAGTC/ZEN/TGGCCCCTCC/3IABkFQ/-3‟ 
Wild type Probe 5‟- /5HEX/CTCTTAGGT/ZEN/CTGGCCCCTC/3IABkFQ/ -3‟ 
TP53 c.584T>C 
 
Forward Primer 5‟- CTGATTGCTCTTAGGTCTG -3‟ 
Reverse Primer 5‟- TTCTGTCATCCAAATACTCC -3‟ 
Mutant type Probe 5‟- /56-FAM/CAGCATCTT/ZEN/ACCCGAGTG/3IABkFQ/ -3‟ 
Wild type Probe 5‟- /5HEX/CAGCATCTT/ZEN/ATCCGAGTGG/3IABkFQ/ -3‟ 
TP53 c.592G>T 
 
Forward Primer 5‟- CTCTGATTCCTCACTGATTG -3‟ 
Reverse Primer 5‟- TTCTGTCATCCAAATACTCC -3‟ 
Mutant type Probe 5‟- /6-FAM/ATCTTATCC/ZEN/GAGTGTAAGGAA/IABkFQ/ -3‟ 
Wild type Probe 5‟- /HEX/TTATCCGAG/ZEN/TGGAAGGAAAT/IABkFQ/ -3‟ 
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TP53 C.636delT Forward Primer 5'- AGT TGC AAA CCA GAC CTC -3' 
 Reverse Primer 5'- TGT GGA GTA TTT GGA TGA CA 3' 
 Mutant type Probe 5'- /56-FAM/CCA CAC TAT /ZEN/GTC GAA AGT GTT /3IABkFQ/ -3' 
 Wild type Probe 5'- /5HEX/ACC ACA CTA /ZEN/TGT CGA AAA GTG /3IABkFQ/ -3' 
TP53 c.659A>G Forward Primer 5‟-AGTTGCAAACCAGACCTCA -3‟ 
 Reverse Primer 5‟-TGTGGAGTATTTGGATGACAGA -3‟ 
 Mutant type Probe 5‟-/6-FAM/CTCACAGGG/ZEN/CACCACC/IABkFQ/ -3‟ 
 Wild type Probe 5‟-/HEX/CGGCTCATA/ZEN/GGGCACCA/IABkFQ/ -3‟ 
TP53 c.743G>A Forward Primer 5‟- CAACTACATGTGTAACAGTTCCTG -3‟ 
 Reverse Primer 5‟- GAGTCTTCCAGTGTGATGATGG -3‟ 
 Mutant type Probe 5‟-/6-FAM/ATGAACCAGAGGCCCATCCT/IABkFQ/ -3‟ 
 Wild type Probe 5‟- /HEX/CATGAACCG/ZEN/GAGGCCCATC/3IABkFQ/ -3‟ 
TP53 c.939delC Forward Primer 5‟- CTCCATCCAGTGGTTTCTTC -3‟ 
 Reverse Primer 5‟- TATCACCTTTCCTTGCCTCT-3‟ 
 Mutant type Probe 5‟- /56-FAM/AGAGGACTG/ZEN/GTGTTGTTGG/3IABkFQ/ -3‟ 
 Wild type Probe 5‟- /5HEX/AGAGGAGCT/ZEN/GGTGTTGTTG/3IABkFQ/ -3‟ 
ZBED4 c.1094C>T Forward Primer 5‟- TACTCCACCCCTCCCACTCT -3‟ 
 Reverse Primer 5‟- CTTTACTGGAGACGAGGACACAGA -3‟ 
 Mutant type Probe 5‟-/6-FAM/TTCCTTGCT/ZEN/GCCGCTGGAC/IABkFQ/ -3‟ 
 Wild type Probe 5‟-/HEX/CCTTGCTGC/ZEN/CGCCGGAC/IABkFQ/ -3‟ 
 
Optimization of Melting Temperature (Tm) 
In order to determine the optimal melting temperature, an initial gradient ddPCR assay for the 
ctDNA and/or FFPE DNA samples of each specific patient sample was prepared (Table 2.3). 
Appropriate controls were used in the study to help standardize the protocols. UltraPure 
DNAse/RNAse Free Distilled Water [Thermo Fischer Scientific, USA ref. 1097715] was 
used as the negative control in order to detect false-positive droplets that may be derived 
from non-specific binding of probes, primer dimer formation or cross-contamination between 
samples. Human Genomic DNA [Roche, Switzerland] diluted to 1:150 was then used as the 
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wild-type positive control. Once the mastermix was pipetted into the wells, the 96-well plate 
was then temporarily sealed and subjected to centrifugation using the Select Spin Plate 
Centrifuge [Select BioProducts, USA].  
 
Table 2.3. Volume (µL) of reagents used for the gradient ddPCR assay 
Reagent Volume (µL) 
Supermix for Probe (No dUTPs) 11 
Forward Primer 0.66 
Reverse Primer 0.66 
Mutant Type Probe 0.22 
Wild Type Probe 0.22 




Droplets were generated from each sample through the use of the QX200™ AutoDG™ 
Droplet Digital™ PCR System [Bio-Rad, USA] as per the manufacturer‟s specification for 
“Probes” reagents. The plate containing the newly generated droplets was then sealed using a 
PCR Thermal Seal RT2KK™ [Excel Scientific Ltd, USA]. PCR amplification was then 
carried out using the C1000 TouchTM Thermal Cycler [Bio-Rad, USA] following the reaction 







Table 2.4. Reaction setup for the gradient ddPCR assay 
Cycle Step Temperature Time 
Enzyme Activation 95oC 10:00 min 
Denaturation 94oC 0:30 sec 
Annealing/Extension 52-62oC 1:00 min 
Enzyme Deactivation 98oC 10:00 min 
Hold 12oC   
 











Upon amplification, the target wild type and mutant droplet concentration were then 
quantified using the QX200™ Droplet Reader (Bio-Rad, USA), which works by passing the 
droplets from the wells through a two-color detector and subsequently classifying the droplets 
as either positive or negative depending on their fluorescence amplitude (Olmedillas-López et 
al., 2017). The samples were evaluated through the Rare Event Detection (RED) experiment 
and the fluorescent probes were measured using FAM for the mutant type and HEX for the 





The acquired results were then exported into the QuantaSoft Analysis Pro Software [Bio-Rad, 
USA] for further data analysis. A threshold was manually set for each assay in order to 
distinguish the positive from the negative background droplets and to determine any false-
positives and false-negatives. The temperature at which the assay was observed to have the 
best separation of mutant/wild type to the background droplets was considered to be the 
optimal melting temperature (Tm).  
 
Optimization of the Multiplex ddPCR assay 
An initial ddPCR run with the optimized Tm was done following the assay shown in Table 
2.6, in order to observe the initial mutant/wild type droplet concentration of each gene in 
patient samples prior the multiplex ddPCR assay.  
 
Table 2.6. Volume (µL) of reagents used for the initial multiplex ddPCR assay 
 Assay 1 Assay 2 
Mastermix 11 11 
Assay 1 Forward Primer 0.66 - 
Reverse Primer 0.66 - 
 
Mutant Type Probe 0.22 - 
Wild Type Probe 0.22 - 
Assay 2 Forward Primer - 0.66 
Reverse Primer - 0.66 
 
Mutant Type Probe - 0.22 
Wild Type Probe - 0.22 
Water 3.24 3.24 
Sample 6 6 




Once the initial mutant/wild type droplet concentration for each gene was determined, the 
patient samples were then subjected to multiplex ddPCR through adjusting the primer and 
probe concentration to generate two ideally separated fluorescence amplitude bands of 
tumour-specific gene mutation assays in a single ddPCR reaction. Shown in Table 2.7 is an 
example of a multiplex ddPCR assay.  
 
Table 2.7. Volume (µL) of reagents used for an example of a sample multiplex ddPCR assay 
 Multiplex Assay 
Mastermix 11.0 
Assay 1 
Forward Primer 0.66 
Reverse Primer 0.66 
 
Mutant Type Probe 0.22 
Wild Type Probe 0.22 
Assay 2 
Forward Primer 0.66 
Reverse Primer 0.66 
 
Mutant Type Probe 0.22 





Multiplex ddPCR assay for serial blood collection cycles 
Once the multiplex ddPCR assay was optimized, the assay was then carried out on ctDNA 
extracted from several blood collection cycles of patients. Upon amplification, the mutant 
droplet concentration for each cycle was quantified using the QX200™ Droplet Reader (Bio-
Rad, USA) and evaluated through the Rare Event Detection (RED) experiment. The 
fluorescent probes were measured using FAM for the mutant type and HEX for the wild type 
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target. Using the QuantaSoft Analysis Pro Software [Bio-Rad, USA], a threshold was set for 
each assay in order to differentiate the two groups of tumour-specific mutant droplets and 
determine any false-positives and false-negatives.  
 
Data Analysis 
The acquired concentration data (copies per µL reaction) were then exported to Microsoft 
Excel and the final mutant droplet concentration (mutation copies per mL plasma ± SEM) for 
each mutation assay in different plasma collection cycles was calculated as follows.  
 
            
                           
                                                 
                          
 
  
A line graph was then generated to elucidate the variation in droplet concentration of two 
tumour-specific mutations against different blood collection cycles.   
 
MPI AND EPA REGULATIONS 
The study employed the standard regulations for handling clinical blood samples and 
chemicals. Appropriate cabinets were used in storage of various chemicals that were used in 
the study. All samples and solution used in the study were labelled properly. Safety glasses, 
gloves, closed footwear and laboratory gowns were worn at all times during any part of the 
experiment. All gloves, used pipette tips, disposable lab wares, and other laboratory 
biohazard wastes were placed in the appropriate bags/bins. All the equipment, reagents, and 
gene-specific primers and probes used in the study were provided by the Cancer Genetics 






A number of metastatic breast cancer patient samples (BRC001, BRC005, BRC006, 
BRC007, BRC009 and BRC010) had already been sequenced and tested by Sarah Parackal in 
partial fulfilment of her MSc project in 2018. Further plasma samples were however collected 
and tested for these patients in this study and the overall results were included in this thesis to 
provide more comprehensive data on these patients.  
 
An initial protocol for the multiplex ddPCR of patient M032 was previously developed by 
Wilson Mitchell in partial fulfilment of his University of Otago Summer Studentship report 
in 2019, based on prior publications (Alcaide et al., 2016; Taly et al., 2013). The personalized 
mutation assays used for the ctDNA analysis of advanced colorectal cancer patients had 














CTDNA ANALYSIS OF BREAST CANCER 
 
STUDY DESIGN 
In this study, ctDNA was investigated as a highly sensitive and inherently specific biomarker 
that can potentially provide an informative and accurate measure of the tumour burden in 
metastatic breast cancer. Although ctDNA only comprises a small fraction of the total cell 
free circulating DNA found in blood, advances in the accuracy and extent of analysis of 
Targeted NGS have enabled the rapid and cost-effective identification of tumour-specific 
somatic alterations in individual tumours, and these was used to design personalized ddPCR 
assays to monitor the tumour dynamics and quantify circulating tumour DNA in serially 
collected plasma samples (Dawson et al., 2013; Smith et al., 2019).  
 
Clinical information including breast cancer molecular subtypes, results of Computed 
Tomography (CT) imaging scans, FFPE blocks from primary tumour/tissue biopsy specimen, 
and serial plasma samples were collected from 34 women from New Zealand undergoing 
systemic therapy for metastatic breast cancer. Sixteen (16) breast cancer patients were 
recruited from Auckland and the remaining 18 patients were from Dunedin. To maintain 
anonymity, each patient was referred to by their study ID.  
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ANALYSIS OF DNA LIBRARIES USING BIOANALYZER  
Sequencing analysis requires consistent, high-quality intact DNA isolated from every patient 
sample without any residual traces of proteins, salts, or other contaminants to ensure optimal 
activity of the library enzymes necessary for targeted enrichment. Intact DNA provides better 
coverage uniformity and generally yields better results than fragmented DNA due to the 
overlaying space between primers (“QIAseq TM Targeted DNA Panel Handbook,” 2017). 
However, since FFPE DNA is usually damaged and fragmented, the integrity of patients‟ 
DNA samples were first assessed using Agilent Bioanalyzer with High Sensitivity DNA Kit 
in order to verify if the DNA used for sequencing was intact and not overly fragmented. 
Shown in Figure 3.1 is a typical Bioanalyzer result for a high quality intact FFPE DNA. 
 
 
Figure 3.1. Bioanalyzer result to check for intact ctDNA and/or FFPE DNA after extraction 
 
The number of UMIs sequenced correlates with the original DNA input amount and directly 
impacts the variant detection sensitivity. An input of more than the required amount (100ng 
for high quality FFPE DNA) will potentially overload the QIAseq Targeted DNA system 
(“QIAseq TM Targeted DNA Panel Handbook,” 2017).  Thus, sample concentration was first 
determined before the library preparation to ensure that enough UMIs can be sequenced for 
33 
 
variant detection. The concentration of the FFPE DNA (Table S1) and gDNA (Table S2) 
extracted from individual patient samples is shown in Appendix C.  
 
Moreover, although DNA is enzymatically fragmented before target enrichment PCR, the 
intact FFPE DNA samples were still subjected to initial fragmentation to ~200bp before the 
library preparation step to ensure optimal Targeted NGS analysis. The samples are then 
evaluated with Fragment Analyzer to verify if the FFPE DNA and ctDNA are fragmented to 
the correct size. Shown in Figure 3.2 is a typical Fragment Analyzer result for fragmented 
FFPE DNA.  
 
 
Figure 3.2. Fragment analyzer result for DNA Fragmentation to ~200bp before the library 
preparation step of Targeted NGS 
 
The specific libraries for each breast cancer sample were then prepared using QIAseq 
Targeted DNA Panel for Human Breast Cancer (DHS-001Z) on the Illumina NGS platform 
(MiSeq®). This specific QIAseq panel comprehensively covers known driver mutations and 
hotspots. After the library was constructed and purified, another Agilent Bioanalyzer run was 
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done to ensure that the DNA libraries were in the correct fragment size and not over-
amplified. Libraries prepared for Illumina instruments demonstrate a size distribution 
between 300-1000bp. Shown in Figure 3.3 is a properly prepared DNA library while Figure 
3.4 shows an over-amplified library which are usually single-stranded libraries with correct 
size but appear as “larger fragments” due to secondary structure. Library over-amplification 
is normal and should not affect the sequencing results (“QIAseq TM Targeted DNA Panel 
Handbook,” 2017).  
 
 
Figure 3.3. Bioanalyzer result for properly prepared libraries (~300-1000bp)  
 
Figure 3.4. Bioanalyzer result for over-amplified libraries 
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IDENTIFICATION OF TUMOUR-SPECIFIC MUTATIONS 
Rare or difficult to detect tumour-associated driver mutation markers were then identified in 
individual tumours by sequencing the prepared libraries isolated from both FFPE DNA and 
ctDNA in order to account for possible tumour heterogeneity. However, analysis of the 
sequencing data revealed both acquired somatic genomic alterations specific for each patient 
and germline variants which caused difficulty in the selection of suitable mutations for 
ctDNA analysis. To account for possible germline mutations, we developed an analysis 
pipeline, previously described in Chapter 2, to accurately identify pathogenic somatic 
mutations and exclude germline variants (Figure 3.5). 
 
 
Figure 3.5. Analysis pipeline for the selection of pathogenic somatic mutations. 
 
However, even with these restrictions, several mutation assays that were supposedly 
pathogenic but were actually germline were still selected. Thus, to improve and provide a 
more cost-effective ctDNA analysis, normal genomic DNA isolated from the buffy coat was 






Personalized mutation assays were then developed through custom design of specific primer 
and probes to target the identified genomic alterations for the ddPCR analysis of breast 
cancer patient plasma samples. The optimal melting temperature (Tm) was determined using 
gradient ddPCR (Figure 3.6) with Human Genomic DNA [Roche, Switzerland] utilised as the 
wild-type positive control.  
 
A total of 34 women with metastatic breast cancer were recruited in the study but only 30/34 
patients underwent targeted sequencing for ctDNA analysis. The other four patients 
(BRC089, BRC091, BRC096, and BRC098) only had 1- 2 available serial blood samples and 
it was decided not to analyse them further. Overall, 18/30 (60%) patients were identified with 
genomic alterations, primarily in TP53 (45%), PIK3CA (25%), KRAS (5%), BRCA1 (5%), 
BRCA2 (5%), CDH1 (5%), ZBED4 (5%), and ESR1 (5%) genes, suitable for ctDNA analysis. 
Shown in Table 3.1 are the tumour-specific mutations identified for each patient with their 
optimized Tm.  
 
All these pathogenic mutations were identified in the archival tumour DNA except for one 
patient (BRC002) who had no significant driver somatic mutations in its FFPE DNA. A TP53 
mutation was instead identified upon the Targeted NGS of the patient‟s ctDNA sample, 













Figure 3.6. Optimization of Tm for personalized assays using Gradient ddPCR. The blue 
droplets are the mutant type, whilst the green are the wild type droplets. The grey droplets 
represent the background droplets that are neither mutant nor wild type. The temperature at 
which the mutant and wild type droplets were observed to be ideally separated was chosen as 











Sample Assay Tm (
oC) 
BRC001 TP53 c.288_289insA 58.2 
BRC002 TP53 c.524G>A 60.1 
BRC004 PIK3CA c.1624G>A 56.0 
 BRCA2 c.8049delA 60.1 
BRC005 TP53 c.659A>G 56.0 
BRC006 CDH1 c1171delG 58.2 
BRC007 PIK3CA c.1633G>A 60.1 
BRC008 ESR1 c.1636G>A 60.1 
BRC009 ZBED4 c.1094C>T 60.1 
BRC010 BRCA1 c.349_350delCA 52.7 
BRC012 TP53 c.743G>A 61.3 
BRC013 TP53 c.560-1G>A 58.2 
BRC048 KRAS c.35G>T 60.1 
BRC049 PIK3CA c.1034A>G 58.2 
BRC050 TP53 c.939delA 58.2 
BRC052 TP53 c.592G>T 54.1 
BRC090 PIK3CA c.3140A>G 56.0 
BRC092 TP53 c.584T>C 58.2 
BRC095 PIK3CA c.1633G>A 60.1 
 TP53 c.636delT 58.2 
Table 3.1. Tumour-specific mutations identified for the ddPCR assay of metastatic breast 




Six patients either didn't have any FFPE blocks that were retrievable (BRC011, BRC051, and 
BRC093) or had poor quality of isolated FFPE DNA (BRC003, BRC088, and BRC094). 
Upon sequencing their respective DNA samples, no good mutation markers were found for 
these patients. For instance, the initial DNA extracted from the FFPE tumour block of patient 
ACH011/BRC094 was overly fragmented and after library preparation, the bioanalyzer 
results showed that no libraries were amplified (Figure 3.7). Thus, targeted NGS of the DNA 




Figure 3.7. Bioanalyzer results for patient BRC094. Shown in the left is the bioanalyzer 
result after FFPE DNA extraction, while the figure in the right shows the result after library 
preparation.  
 
Due to time constraints and the unforeseen system fault causing communication error in the 
MiSeq equipment used in the laboratory, the final targeted NGS run for the remaining 6/30 
patients (BRC053, BRC097, BRC099, BRC100, BRC101, and BRC102) has been delayed. 
The prepared libraries for these patients were successfully clustered but the machine suddenly 
stopped receiving data from Illumina and thus, the system has timed out and abruptly stopped 
the run. Once the MiSeq is repaired, the remaining patient samples will be analysed but this 
will be outside the scope of this thesis. The summary of the current progress in ctDNA 




Figure 3.8. Overview of results for the ctDNA analysis of Metastatic Breast Cancer patients 
 
QUANTIFICATION OF CTDNA IN SERIAL PLASMA SAMPLES 
The efficacy of ctDNA analysis for the surveillance of metastatic breast cancer was then 
explored by comparing the detected ctDNA levels to patient‟s response to treatment and 
overall clinical endpoints. Personalized ddPCR assays were used to quantify tumour-specific 
mutations in the cell-free ctDNA isolated from a total of 175 patient plasma samples taken 
serially during the clinical course. The ctDNA isolated from individual patients and target 
sequence-specific fluorescent probe and primers were first partitioned into thousands of 
reaction droplets. After the successful amplification of the target sequences, each droplet was 
detected through ddPCR with either a positive fluorescence (amplified with the target 
sequence) or a binary readout (negative). The threshold of the ddPCR assay was then 
manually set with the negative controls as reference in order to define „rain partitions‟ that 
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should be excluded from the analysis (Olmedillas-López et al., 2017; Jackson et al., 2016; 
Olsson et al., 2015).  
 
The precise calculation of the total mutant allele concentration was then facilitated with the 
use of Poisson‟s correction on the known droplet volume and the fraction of positive droplets 
relative to the total number of droplets. This enables the "absolute quantification" of the 
amplifiable targets present in the input ctDNA sample, thereby making calibration curves 
unnecessary for ddPCR (Olmedillas-López et al., 2017; Jackson et al., 2016; Olsson et al., 
2015). Shown in Figure 3.9 is an optimized ddPCR mutation assay with robust and distinct 
droplet signals. Each tumour-specific mutation assay was run in at least 3 replicates and 




Figure 3.9. Optimized 1D (bottom) and 2D (top) plot of droplet fluorescence amplitude 
obtained from a single mutation ddPCR run. The blue droplets are the mutant type, whilst 
the green are the wild type droplets. The grey droplets represent the background droplets that 
are neither mutant nor wild type, and the orange droplets are detected as both mutant and 





Patient BRC001 was a 55 year-old female diagnosed with breast cancer in 2014. Upon 
subsequent right mastectomy in November 2014, it was revealed that the patient had a poorly 
differentiated primary tumour (2-5cm) but with no focal areas of activity to suggest bony 
metastasis. Immunohistochemistry of the primary tumour however reveals that the tumour 
was HER2-positive, but oestrogen (ER-) and progesterone receptor (PR-) negative.  
 
BRC001 completed adjuvant radiotherapy in August 2015 and was then treated with 6 cycles 
of adjuvant FEC-docetaxel and trastuzumab until April 2016. However in December 2016, it 
was noted that although the patient‟s liver lesions were unchanged from previous scans, a 
new heterogeneous area was found and the patient was diagnosed with metastatic breast 
cancer. In February 2017, CT scans showed that although the liver lesions remained 
unchanged and the pancreatic lesions decreased in size, the patient was still however 
diagnosed with an incurable metastatic breast cancer.  
 
The patient was then enrolled into the study in February 2017 and archival-tumour tissue 
samples were analysed to identify somatic genomic alterations. Targeted NGS of the FFPE 
DNA extracted from the primary tumour specimen of BRC001 identified that the patient had 
a novel TP53 c.288_289insA mutation. A specific ddPCR assay was designed and optimized 
with a melting temperature of 58.2oC. Results show that the FFPE DNA had 154.9 ± 1.74 
copies/µL of the TP53 mutation while no mutant copies were detected in the gDNA samples.  
Levels of ctDNA were then analysed from 14 cycles of plasma samples collected from 
February 2017 to April 2018 (Figure 3.10).  
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Previous study by S. Parackal analysed the first 11 cycles for patient BRC001. The remaining 
plasma cycles were then collected and analysed in this study. The highest concentration of 
ctDNA (119.57±21.3 copies/mL) was detected in the first cycle. BRC001 then commenced 
treatment with weekly pertuzumab, Herceptin, and vinorelbine and the levels of ctDNA 
started to decrease in March 2017. The results suggest possible correlation with following CT 
scans from April 2017 which revealed a reduced size of the hypodense lesions within the 
liver and anterior mediastinum.  
 
In June 2017, vinorelbine chemotherapy was stopped but maintenance pertuzumab and 
Herceptin were continued. By August 2017, the patient had a significant clinical 
improvement and was withdrawn from the study by the end of April 2018. In line with the 
stable diagnosis of patient BRC001, ctDNA results show that no mutant copies were detected 
in the subsequent plasma cycles until April 2018. However, just two months after (June 
2018), the radiographic imaging scans revealed novel liver metastases and a significant 
enlargement of new cystic/solid mass in the body of pancreas, thus indicating a progression 
of disease. Unfortunately, there are no more patient samples available to verify whether the 















Figure 3.10. Concentration (mean copies/mL plasma ± SE) of TP53 c.288_289insA 
mutation in the ctDNA of serial blood collection cycles from patient BRC001. Levels of 
TP53 mutation detected from the ctDNA of 14 cycles of plasma samples from February 2017 
to April 2018 were analysed and quantified using ddPCR. The mean mutation copies/mL 
plasma was calculated and plotted with the standard error (SE) as error bars. ctDNA was only 
detected in the first cycle of plasma collection. No mutation copies were detected in the 
following 13 cycles from March 2017 to April 2018. CT imaging scans also showed that the 
patient was clinically improving and responding to treatments. However, BRC001 was later 









Patient BRC002 was diagnosed with primary breast cancer in November 2012 which was 
then later diagnosed with metastases to the chest wall and bone in October 2016. The 
patient‟s primary tumour was then collected in February 2017 and pathology reports showed 
a moderately differentiated invasive adenocarcinoma. Immunohistochemistry of the primary 
tumour also revealed that BRC002 had Luminal B breast cancer and was positive for HER2, 
oestrogen (ER+) and progesterone receptors (PR+). The patient declined any adjuvant 
treatment and instead received aromatase inhibitor and zoledronic acid to stop the production 
of oestrogen.    
 
In March 2017, the patient was recruited into the study and the tumour tissue samples were 
analysed to identify somatic genomic alterations. No significant driver somatic mutations 
were identified upon the targeted NGS of the FFPE DNA extracted from the primary tumour 
specimen of BRC002. However, upon targeted sequencing of the ctDNA from the first cycle 
of BRC002 collected in March 2017, it was previously identified by S. Parackal that the 
patient had a TP53 c.524G>A mutation. A specific ddPCR assay was designed and optimized 
by Donghui Zou with a melting temperature of 60.1oC. Results show that no mutant copies 
were detected in the gDNA samples. However, the plasma samples collected from the first 
cycle had already been used up from the previous study and only the remaining 12 cycles of 
plasma collection from April to August 2018 was analysed in this study (Figure 3.11).  
 
Low levels of ctDNA (<10.5 copies/mL) were detected in the first 7 cycles from April to 
September 2017. The results suggests possible correlation with the clinical information since 
in June 2017, CT scans revealed that the patient was responding to treatments. However in 
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November 2017, BRC002 was diagnosed with tumour recurrence in the right sided 
axillary/pectoral region and at right lateral chest wall. Unfortunately, there are no patient 
samples available to verify whether the ctDNA levels correlate with the disease progression 
of BRC002 since two cycles of the monthly blood collection were missed and no plasma 
samples were collected in October and November 2017. 
 
A month after the progressive diagnosis, another cycle of plasma sample was collected in 
December 2017 and the ctDNA levels rose up to its highest concentration (534.64 ± 38.03 
copies/mL) throughout the study. The patient then commenced treatment with tamoxifen.  
The levels of ctDNA started to decrease to 53.48 ± 4.99 copies/mL in February 2018 and then 
increased again (241.54 ± 28.86 copies/mL) in April 2018. According to the CT results, the 
disease continued to be progressive with soft tissue metastases in the right chest wall and 
axilla. ctDNA started to decrease to 44.26 ± 17.50 copies/mL towards the end of April 2018 
and then increased again (228.80 ± 29.62 copies/mL) in May 2018. In the last cycle of 
plasma samples collected in August 2018, the ctDNA levels finally dropped down to only 
5.76 ± 3.00 copies/mL. The patient ceased blood collection and no further clinical 














Figure 3.11. Concentration (mean copies/ mL plasma ± SE) of TP53 c.524G>A mutation 
in the ctDNA of serial blood collection cycles from patient BRC002. Levels of TP53 
mutation detected from the ctDNA of 12 cycles of plasma samples from April 2017 to 
August 2018 were analysed and quantified using ddPCR. The mean mutation copies/mL 
plasma was calculated and plotted with the standard error (SE) as error bars. Low levels of 
ctDNA were detected in the first 7 cycles from April to September 2017. BRC002 was then 
diagnosed with tumour recurrence in November 2017 and then in the cycle 8 of plasma 
collection (December 2017), the ctDNA levels increased up to its highest peak. The patient 
was then treated with tamoxifen and the ctDNA levels started to decrease. In April 2018, 
ctDNA started to increase again and the patient was diagnosed with disease progression. 
Levels of ctDNA then started fluctuating until only low levels were detected in the 12th cycle. 






Patient BRC004 was diagnosed with breast cancer with leptomeningeal involvement in 
February 2011. Immunohistochemistry of the primary tumour however revealed that the 
patient had Luminal A breast cancer and was positive for oestrogen (ER+) and progesterone 
receptors (PR+) but negative for the HER2 receptor. Thus, the patient received AC 
chemotherapy (Adriamycin/ Doxorubicin and Cyclophosphamide), Tamoxifen and 
radiotherapy.  
 
In September 2016, the patient was diagnosed with metastatic disease and was therefore 
given goserelin and aromatase inhibitor with zoledronic acid in October 2016.   MRI scans 
from March 2017 then revealed that the patient had stable disease. The patient was enrolled 
into the study in June 2017. Targeted NGS of the FFPE DNA extracted from the primary 
tumour specimen of BRC004 determined that the patient had BRCA2 c.8049delA (identified 
by S. Parackal) and PIK3CA c.1624G>A mutations. Specific ddPCR assays were designed 
and optimized with a melting temperature of 56.0oC and 60.1oC for the PIK3CA and BRCA2 
assay respectively. Results show that the FFPE DNA had 12.48 ± 0.31 copies/µL of the 
PIK3CA mutation while there were 3.9 copies/µL of the BRCA2 mutation. No mutant copies 
were detected in the gDNA samples. Levels of ctDNA from 4 cycles of plasma samples 
collected from June 2017 to December 2018 were analysed in this study (Figure 3.12).  
 
No mutant copies were detected in all available cycles of plasma samples throughout the 
study, except for the last cycle collected in December 2018 which had 6.44 ± 1.44 copies/mL 
of the PIK3CA mutation. The BRCA2 mutation was however not detected in the same cycle. 
The results suggest possible correlation with the CT imaging results since the patient has 
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been diagnosed with a stable disease throughout the study. The patient ceased blood sample 
collection and was withdrawn from the study in December 2018. No further clinical 




Figure 3.12. Concentration (mean copies/mL plasma ± SE) of PIK3CA c.1624G>A and 
BRCA2 c.8049delA mutation in the ctDNA of serial blood collection cycles from patient 
BRC004.  Levels of PIK3CA and BRCA2 mutation detected from the ctDNA of 4 cycles of 
plasma samples from June 2017 to December 2018 were analysed and quantified using 
ddPCR. The mean mutation copies/mL plasma was calculated and plotted with the standard 
error (SE) as error bars. Low levels of ctDNA were detected in all the available cycles of 








Patient BRC005 was a 73 year-old female diagnosed with a broad malignant appearing 
tumour in the outer quadrant of the upper right breast in October 2013. No further lesions 
were found, however, immunohistochemistry of the primary tumour revealed that the patient 
had Triple Negative Breast Cancer (TNBC), characterized by negative HER2 (-), oestrogen 
(ER-) and progesterone receptors (PR-).  
 
The patient completed adjuvant FEC-docetaxel chemotherapy in April 2014 and adjuvant 
radiotherapy to right chest wall in June 2014.  Then, in March 2017, the patient was 
diagnosed with a metastatic breast cancer with bilateral lung involvement. CT scans revealed 
a homogeneous opacity present in the right middle lobe and a left lung lesion biopsy was 
found consistent with the metastatic breast carcinoma. The patient was then recruited into the 
study in April 2017. 
 
Targeted NGS of the FFPE DNA extracted from the primary tumour specimen of BRC005 
identified that the patient had a novel TP53 c.659A>G mutation. A specific ddPCR assay was 
previously designed and optimized by S. Parackal, with a melting temperature of 56.0oC. 
Results show that the FFPE DNA had 52.36 ±1.42 copies/µL of the TP53 mutation while no 
mutant copies were detected in the gDNA samples (wild type positive control). Levels of 
ctDNA were then analysed from 17 cycles of plasma samples collected from April 2017 to 
July 2018 (Figure 3.13). 
 
Low levels of ctDNA (<1.00 copies/mL) were detected in the first 8 cycles from April to 
October 2017, as previously analysed by S. Parackal. The remaining plasma cycles were then 
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collected and analysed in this study. In June 2017, the patient underwent right mastectomy 
and a slight improvement was clinically observed in the right middle lobe. Palliative 
vinorelbine chemotherapy was completed with response and the patient then switched to 
palliative letrozole following chemotherapy in August 2017.   
 
In November 2017, the levels of ctDNA started to slowly increase (3.36 ± 1.14 copies/mL) 
until the highest concentration (21.39 ±3.21 copies/mL) was reached in the cycle 17 of 
plasma collection. Clinically, the patient had remained stable and was withdrawn from the 
study in October 2018. However in December 2018, CT scans revealed progression of 
disease with marked enlargement of right lung lesion including endobronchial extension. The 
treatment was then switched to tamoxifen.  However, the disease continued to progress and in 
January 2019; the patient was clinically diagnosed with an incurable breast cancer with 
enlarging lung metastases. Unfortunately, there are no more patient samples available to 

















Figure 3.13. Concentration (mean copies/ mL plasma ± SE) of TP53 c.659A>G mutation 
in the ctDNA of serial blood collection cycles from patient BRC005. Levels of TP53 
mutation detected from the ctDNA of 17 cycles of plasma samples from April 2017 to July 
2018 were analysed and quantified using ddPCR. The mean mutation copies/mL plasma was 
calculated and plotted with the standard error (SE) as error bars. In the first 8 cycles of 
plasma collection, low levels of ctDNA were detected and CT scans revealed that the patient 
had a stable disease. However, the concentration of ctDNA started to slowly increase in cycle 
9 until the highest peak was observed in cycle 17 of plasma collection in August 2018. No 
further blood samples were collected. However, BRC005 was later clinically diagnosed with 








Patient BRC006 was a 59 year-old female diagnosed with breast cancer involving multiple 
large dense areas (multifocal tumour) and ill-defined lesion within right breast in January 
2012. Ultrasound shows palpable tumour in upper breast and numerous large lymph nodes. 
Immunohistochemistry of tissue specimen collected from the core biopsy of multiple lesions 
revealed that the patient had Luminal A breast cancer and was positive for oestrogen 
receptors (ER+) but was negative for progesterone (PR-) and HER2 receptors. 
 
In February 2012, the patient was observed to have a malignancy that occupies the greater 
part of her right breast with three areas in the left breast that are too small to accurately 
characterize but there were no particular features to suggest metastasis. However, in August 
2016, multiple metastatic deposits were observed in the bones of the patient. The patient then 
underwent palliative vinorelbine in September 2016.   
 
Progression of the known bony metastases was observed in November 2016 and a new liver 
metastasis was found in January 2017. Patient BRC006 then commenced palliative 
exemestane (or Aromasin).  In April 2017, appearances of the remaining metastases 
(stomach, bone, liver) were similar to previous scans however a new liver metastasis was 
observed. The patient was enrolled into the study in May 2017 and then started treatment 
with 4 cycles of FEC chemotherapy. All the clinical samples of BRC006 were analysed in the 
previous study by S. Parackal. The results are then included in the thesis to provide a more 




Targeted NGS of the FFPE DNA extracted from the primary tumour specimen of BRC006 
identified that the patient had a novel CDH1 c.1171delG mutation. A specific ddPCR assay 
was designed and optimized with a melting temperature of 58.2oC. Results show that the 
FFPE DNA had 112.42 ±4.84 copies/µL of the CDH1 mutation while no mutant copies were 
detected in the gDNA samples (wild type positive control). Only 3 cycles of plasma samples 
collected from May to June 2017 were analysed (Figure 3.14). 
 
The highest concentration of ctDNA (117.00 ± 13.83 copies/mL) was detected in the first 
cycle. However, the levels of ctDNA immediately dropped down to 1.25 ± 0.75 copies/mL in 
the cycle 2 plasma collected at the end of May 2017. In June 2017, no mutant copies were 
detected and the patient has since ceased to provide blood samples for the study. CT scans 
done towards the end of June 2017 showed that there was a decrease in the thickening of the 
gastric pylorus and the cancer seemed to be well controlled. No new metastatic disease was 
seen and all the succeeding blood tests were unremarkable. Thus, patient BR006 stopped the 
FEC chemotherapy. Further clinical tests were done in August 2017 and the patient was 
assessed as having stable disease. Finally, the patient commenced treatment with tamoxifen 















Figure 3.14. Concentration (mean copies/ mL plasma ± SE) of CDH1 c.1171delG 
mutation in the ctDNA of serial blood collection cycles from patient BRC006. Levels of 
CDH1 mutation detected from the ctDNA of 3 cycles of plasma samples from May to June 
2017 were analysed and quantified using ddPCR. The mean mutation copies/mL plasma was 
calculated and plotted with the standard error (SE) as error bars. The highest ctDNA 
concentration was detected in the 1st cycle of serial plasma collection. The patient was then 
treated with palliative FEC chemotherapy and the ctDNA levels then dropped down in the 
last two available cycles. BRC006 stopped chemotherapy and remained stable until August 









Patient BRC007 was a 43 year-old female diagnosed with primary breast cancer in 
September 2012. The patient underwent a right mastectomy to remove a <0.5cm primary 
tumour which was later characterized through histopathological analysis to have no regional 
lymph node or distant metastasis. Further immunohistochemistry of the primary tumour 
revealed that the patient had HER2-enriched breast cancer and was positive for HER2 
receptor but is negative for both oestrogen (ER-) and progesterone (PR-) receptors. 
The patient underwent 3 cycles of adjuvant TC chemotherapy (Taxotere/docetaxel and 
cyclophosphamide) and trastuzumab until January 2013. Upon further surveillance 
mammogram, it was revealed in March 2017 that the patient had a metastatic breast 
carcinoma with diffuse opacities within both lungs. Highly suspicious metastatic right 
axillary lymph nodes and bony lesions were also observed.  
 
The patient was enrolled into the study in May 2017. Targeted NGS of the FFPE DNA 
extracted from the primary tumour specimen of BRC007 identified that the patient had a 
novel PIK3CA c.1633G>A mutation. A specific ddPCR assay was designed and optimized 
with a melting temperature of 60.1oC. Results show that the FFPE DNA had 48.7 ± 3.01 
copies/µL of the PIK3CA mutation while no mutant copies were detected in the gDNA 
samples (wild type positive control). Levels of ctDNA from 12 cycles of plasma samples 
collected from May 2017 to July 2018 were analysed (Figure 3.15). 
 
Previous study by S. Parackal analysed the first 9 cycles for patient BRC007. The remaining 
plasma cycles were then collected and analysed in this study. The highest concentration of 
ctDNA (61.3 ± 5.66 copies/mL) was detected in the first cycle. Clinical tests done in May 
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2017 then revealed possible small lytic metastases in vertebral bodies. BRC007 was therefore 
given palliative pertuzumab, Herceptin, and vinorelbine. The dosage for vinorelbine was 
however reduced by 10% from cycle 2 onwards. In the following cycles, the concentration of 
ctDNA dropped down and was consistently detected in the low levels (<4.00 copies/mL) for 
the subsequent cycles of plasma samples collected from the end of May 2017 to July 2018. 
The results from the ctDNA analysis suggest possible correlation with the acquired clinical 
information for BRC007.  
 
According to the results of CT imaging in June 2017, it was observed that the lymph nodes 
metastasis in right axilla returned to normal size. Lung change have also partially resolved 
and no new metastases were observed. However, the skeletal metastases have become more 
sclerotic and thus, the patient was then given palliative radiotherapy. Moreover, it was noted 
in August 2017 the patient was clinically doing well and had received the final cycle of 
chemotherapy. The patient ceased collection of blood samples in July 2018 but the disease 
had not clinically progressed by October 2018. No further clinical information were acquired 

















Figure 3.15. Concentration (mean copies/mL plasma ± SE) of PIK3CA c.1633G>A 
mutation in the ctDNA of serial blood collection cycles from patient BRC007. Levels of 
PIK3CA mutation detected from the ctDNA of 12 cycles of plasma samples from May 2017 
to July 2018 were analysed and quantified using ddPCR. The mean mutation copies/mL 
plasma was calculated and plotted with the standard error (SE) as error bars. The highest 
concentration of ctDNA was detected in the first cycle of plasma collection. Low levels of 
ctDNA were then detected in the following 11 cycles from the end of May 2017 to July 2018. 












Patient BRC008 has been diagnosed with a locally advanced metastatic breast cancer to the 
spine in October 2016. Immunohistochemistry of the tumour tissue specimen from biopsy 
revealed that the patient had Luminal B breast cancer and was positive for oestrogen (ER+), 
HER2 (+) and progesterone (PR+) receptors. In November 2016, the patient commenced 
docetaxel/Herceptin/pertuzumab and a partial response from CT scans were observed in 
February 2017.  
 
The patient was enrolled into the study in April 2017. Targeted NGS of the FFPE DNA 
extracted from the primary tumour specimen of BRC008 identified that the patient had a 
novel ESR1 c.1636G>A mutation. A specific ddPCR assay was designed and optimized with 
a melting temperature of 60.1oC. Results show that the FFPE DNA had 12.48 ± 0.27 
copies/µL of the ESR1 mutation while no mutant copies were detected in the gDNA samples. 
Levels of ctDNA from 5 cycles of plasma samples collected from May 2017 to May 2018 
were analysed (Figure 3.16). The patient however remained stable all throughout the study 
and no mutant copies were detected in all the available cycles. BRC008 ceased blood sample 












Figure 3.16. Concentration (mean copies/mL plasma ± SE) of ESR1 c.1636G>A 
mutation in the ctDNA of serial blood collection cycles from patient BRC008. Levels of 
ESR1 mutation detected from the ctDNA of 5 cycles of plasma samples from May 2017 to 
May 2018 were analysed and quantified using ddPCR. The mean mutation copies/mL plasma 
was calculated and plotted with the standard error (SE) as error bars. ctDNA was not detected 
in all the available cycles of plasma samples and the patient remained clinically stable all 









Patient BRC009 was a 49 year-old female diagnosed with a right inflammatory breast cancer 
in December 2015 with no features to suggest metastatic disease. A high grade infiltrating 
ductal carcinoma with regional spread to the right axillary lymph node was however 
identified from a core biopsy of the primary tumour. BRC009 then underwent right 
mastectomy and clearance of axillary nodes in April 2016. Immunohistochemistry of the 
primary tumour revealed that the patient had Luminal A breast cancer and was negative for 
both HER2 (-), and progesterone receptors (PR-) but positive for oestrogen receptors (ER+).  
 
In January 2016, multiple but small axillary lymph nodes were observed on the right breast 
however there was still no definite metastatic disease. The patient underwent neoadjuvant TC 
chemotherapy and completed this treatment in March 2016. Multiple small foci of invas ive 
carcinoma were then observed in April 2016. The patient was given adjuvant radiotherapy 
until June 2016 and then was treated with adjuvant tamoxifen in July 2016. Radiology tests 
done in February 2017 however revealed multiple metastatic deposits and abnormal bone 
scans thereby highly suggestive of metastatic disease. In March 2017, the patient was treated 
with palliative radiation to the spine and letrozole upon identification of a visceral metastatic 
disease.  CT imaging tests from May 2017 then showed progression of the metastatic disease 
with multiple liver metastases and prominent bony metastases throughout the spine and 
pelvis. The patient ceased treatment with letrozole and then underwent palliative weekly 
doxorubicin.   
 
The patient was enrolled into the study in June 2017. Previous study by S. Parackal identified 
a BARD1 c.1972C>T mutation, however initial gradient ddPCR run revealed that the 
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designed assay had cross reactivity. Thus, in this study, another Targeted NGS run was 
carried out on the FFPE DNA extracted from the primary tumour specimen of BRC009 and a 
novel HERC1 c.14368T>C mutation was identified. A specific ddPCR assay was designed 
and optimized with a melting temperature of 58.2oC. Results show that the FFPE DNA had 
64.80 ± 0.33 copies/µL of the HERC1 mutation while no mutant copies were detected in the 
gDNA samples. However, when the assay was tested on ctDNA samples, the fractional 
abundance of the mutant target was detected to be consistently at approximately 50%. The 
identified HERC1 assay is most likely a non-pathogenic germline variant to patient BRC009 
and would therefore not be a good biomarker for ctDNA analysis.  
 
From the same sequence data, a different ZBED4 c.1094C>T mutation assay was identified. 
This specific assay was not initially considered for the analysis since the mutation had no 
COSMIC data and was considered to have an “Uncertain Significance” in VARSOME. 
Moreover, the ZBED4 mutation had VMF=0.5833333 and a relatively higher frequency 
(0.000145) in normal population compared to previously considered assays, which can 
indicate that the assay may be heterozygous or homozygous germline mutations. However, 
since this assay was readily available in the laboratory, ZBED4 c.1094C>T mutation (Tm= 
60.1oC) was thereby tested for ctDNA analysis. Results show that the FFPE DNA had 67.51 
± 1.69 copies/µL of the ZBED4 mutation while no mutant copies were detected in the gDNA 
samples. Levels of ctDNA from 9 cycles of plasma samples collected from June to October 
2017 were then analysed (Figure 3.17). 
 
ctDNA analysis immediately confirmed that the patient had progressive disease. Evidently 
high levels of ctDNA were detected in the cycle 1 (24,414 ± 693 copies/mL) and cycle 2 
(24,721 ± 277 copies/mL) plasma collected in June 2017. The ctDNA then decreased to 
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10,235 ± 265 copies/mL in the 3rd cycle. This suggests possible correlation with CT imaging 
tests which revealed that in July 2017, there was a modest improvement in the patient‟s liver 
function tests, but an extensive disease in liver is still observed. There were difficulties in 
evaluating the liver and bone lesions due to multiplicity but the liver lesions were observed to 
be smaller than previous scans. Moreover, there are no evidence of intracranial metastatic 
disease and no significant changes in the appearance of bone lesions. Overall, it was noted 
that the patient might have a suggestive family history for breast cancer. The ctDNA levels 
then started to rise up again (20,740 ± 323 copies/mL) in the cycle 4 collected towards the 
end of July 2017.  
 
BRC009 completed her palliative weekly doxorubicin in August 2017. The ctDNA then 
dropped down to 12,809 ± 80 copies/mL and then started to immediately increase again in the 
cycle 6 (20,900 ± 610 copies/mL) and cycle 7 (19,995 ± 333 copies/mL) plasma samples. In 
September 2017, treatment was switched back to hormonal therapy with letrozole as 
maintenance treatment following chemotherapy. Consequently, the levels of ctDNA 
decreased in the cycle 8 (16,539 ± 235 copies/mL) and cycle 9 (17,547 ± 198 copies/mL) 
samples. The patient ceased collection of blood samples and was withdrawn from the study in 
October 2017. Palbociclib in addition to letrozole was also given to the patient, however 













Figure 3.17. Concentration (mean copies/mL plasma ± SE) of ZBED4 c.1094C>T 
mutation in the ctDNA of serial blood collection cycles from patient BRC009. Levels of 
ZBED4 mutation detected from the ctDNA of 9 cycles of plasma samples from May to 
September 2017 were analysed and quantified using ddPCR. The mean mutation copies/mL 
plasma was calculated and plotted with the standard error (SE) as error bars. BRC009 had an 
overall progressive disease throughout the study, as confirmed by both ctDNA analysis and 
CT scan results. The highest ctDNA concentration was detected in the cycle 2 of serial 
plasma collection. The patient ceased blood collection in October 2017 but was clinically 









Patient BRC010 was a 52 year-old female diagnosed with left breast tumour with left axillary 
lymph node metastases and probable bone metastases in September 2012. Tests revealed 
suspicious activity in the sternum but there were no features to strongly suggest metastatic 
disease. Further tests showed prominent lymph nodes in left axilla and a large malignant 
appearing tumour in the left breast which deformed the adjacent tissues. 
Immunohistochemistry of the primary tumour also reveals that the patient had Luminal B 
breast cancer and was positive for HER2 (+), oestrogen (ER+) and progesterone (PR+) 
receptors.  
 
In March 2016, scans revealed metastatic disease in the omentum and possible lung 
metastasis. The patient was then treated with palliative letrozole. In April 2016, several 
metastatic deposits were found and the sternum was observed to have tumour throughout. 
Further tests in June 2016 showed mild improvement in the omental disease but deteriorating 
bone metastases and a small speculated lesion in residual left breast were observed. The 
patient was then treated with palliative tamoxifen in October 2016 but was immediately 
stopped due to progressive bone disease. In April 2017, there was a significant increase in the 
number of metastatic deposits scattered throughout the skeleton.  
 
The patient was recruited into the study in May 2017. All the clinical samples of BRC010 
were analysed in the previous study by S. Parackal. The results are then included in the thesis 
to provide a more comprehensive report. Targeted NGS of the FFPE DNA extracted from the 
primary tumour specimen of BRC010 identified that the patient had a novel BRCA1 
c.349_350delCA mutation. A specific ddPCR assay was designed and optimized with a 
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melting temperature of 52.7oC. Results show that the FFPE DNA had 0.183 ± 0.234 
copies/µL of the BRCA1 mutation while no mutant copies were detected in the gDNA 
samples (wild type positive control). Levels of ctDNA from 7 cycles of plasma samples 
collected from May to November 2017 were analysed (Figure 3.18).  
 
The patient remained stable in the first 6 cycles of plasma sample collection and no mutant 
copies were detected from May to August 2017. The results suggest possible correlation with 
the CT scans in May 2017, which revealed deterioration in bone metastases and no liver or 
lung metastases. Persistent omental nodularity was still observed and thus the patient was 
treated with palliative Herceptin and gemcitabine. Further CT scans in July 2017 showed 
stable appearance of extensive bony metastases and no new metastatic disease were seen.  
 
In October 2017, the patient was diagnosed with a progressive incurable metastatic breast 
cancer with increasing omental thickening and enlargement of both ovaries. The patient was 
then treated with palliative capecitabine.  Unfortunately, there are no patient samples 
available to verify whether the ctDNA levels still correlate with the disease progression of the 
patient since no plasma samples were collected between September and October 2017. One 
last cycle of blood sample was collected in November 2017. However, no mutant copies were 













Figure 3.18. Concentration (mean copies/mL plasma ± SE) of BRCA1 c.349_350delCA 
mutation in the ctDNA of serial blood collection cycles from patient BRC010. Levels of 
BRCA1 mutation detected from the ctDNA of 7 cycles of plasma samples from May to 
November 2017 were analysed and quantified using ddPCR. The mean mutation copies/mL 
plasma was calculated and plotted with the standard error (SE) as error bars. ctDNA was not 
detected and CT imaging results revealed that the patient remained clinically stable in the 
first 6 cycles of serial blood collection. Disease progression was diagnosed in October 2017. 
However there were no plasma samples available for ctDNA analysis from September to 









Patient BRC012 was diagnosed with locally advanced metastatic breast cancer in the lungs in 
July 2016. Immunohistochemistry of the tumour tissue collected from biopsy revealed that 
the patient had Luminal B breast cancer and was positive for HER2 (+), oestrogen (ER+) and 
progesterone (PR+) receptors. Thus, in August 2016, the patient was treated with 
docetaxel/Herceptin. However, CT scans from May 2017 revealed progression of the disease. 
In June 2017, the patient was enrolled into the study and then switched treatment to 
capecitabine.  
 
Targeted NGS of the FFPE DNA extracted from the tumour biopsy specimen of BRC012 
previously identified that the patient had a novel BRCA1 c.3756_3759delGTCT mutation. 
This assay (VMF: 0.6944) had no COSMIC information but was identified to be pathogenic 
in VARSOME and is found to have very low frequency in normal population (FREQ: 
0.0000239). A specific ddPCR assay was previously designed and optimized by S. Parackal 
with a melting temperature of 58.2oC. Results show that the FFPE DNA had 176.00 ± 13.88 
copies/µL of the BRCA1 mutation while no mutant copies were detected in the gDNA 
samples (wild type positive control). However, when the assay was tested on ctDNA samples, 
the fractional abundance of the mutant target was detected to be consistently at approximately 
50%. The identified BRCA1 assay is most likely a non-pathogenic germline variant to patient 
BRC012 and would therefore not be a good biomarker for ctDNA analysis.  
 
From the same sequence data, another pathogenic TP53 c.743G>A mutation assay was 
identified in this study. This specific assay was pathogenic in both VARSOME and COSMIC 
(FATHMM prediction: 0.98). Although this assay had VMF=0.52136, TP53 c.743G>A is 
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also found in low frequency (0.0000119) in normal population, which can indicate that the 
assay may be a better biomarker for the ctDNA analysis of BRC012. A specific ddPCR assay 
was previously designed and optimized by Donghui Zou with a melting temperature of 
61.3oC. Results show that the FFPE DNA had 71.90 ± 2.62 copies/µL of the TP53 mutation 
while no mutant copies were detected in the gDNA samples. Fourteen cycles of serial plasma 
samples collected from June 2017 to December 2018 were analysed for ctDNA (Figure 3.19). 
 
Low levels of TP53 mutation (<10.0 copies/mL) were detected in all the cycles of plasma 
samples available for ctDNA analysis. In June 2017, the first cycle was collected and only 
4.21 ± 1.72 mutant copies/mL was detected. The concentration of ctDNA dropped down and 
no mutant copies were detected in cycle 2-4 of the serial plasma samples collected from July 
to August 2017. Further CT scans in September 2017 confirmed that the patient was 
responding to treatment. There are no metastatic disease seen but there was a slight increase 
in the size of the upper lobe nodule. ctDNA levels increased again in the cycle 5 (3.05 ± 0.68 
copies/mL) and cycle 6 (5.55 ± 1.03 copies/mL) collected between September and October 
2017.  
 
No mutant copies were detected from November and December 2017, but then the detected 
ctDNA concentration increased again in cycle 9 (4.23 ± 1.05 copies/mL). The results suggest 
possible correlation with the disease progression diagnosed in February 2018 due to an 
increase in the size of the right upper lobe lung nodule/metastasis. New nodes with disease 
progression were also observed in these regions but no new metastatic disease/disease 
progression was seen elsewhere.  Levels of ctDNA then started to constantly rise up until it 
reached the highest concentration (9.98 ± 1.82 copies/mL) in the cycle 12 sample collected in 
April 2018.  
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The patient was then treated with vinorelbine and the detected ctDNA concentration dropped 
down to 5.26 ± 0.41 mutant copies/mL in the cycle 13 sample collected in June 2018. 
However, the patient was still diagnosed with disease progression. BRC012 ceased blood 
collection and no more mutant copies were detected in the last cycle collected in December 
2018. No further clinical information were acquired for the patient. 
 
 
Figure 3.19. Concentration (mean copies/mL plasma ± SE) of TP53 c.743G>A mutation 
in the ctDNA of serial blood collection cycles from patient BRC012. Levels of TP53 
mutation detected from the ctDNA of 14 cycles of plasma samples from June 2017 to 
December 2018 were analysed and quantified using ddPCR. The mean mutation copies/mL 
plasma was calculated and plotted with the standard error (SE) as error bars. Although low 
levels of ctDNA were detected in all the cycles available for analysis, the fluctuations in the 
concentration of ctDNA suggest potential correlation with the tumour burden of BRC012 






Patient BRC013 was diagnosed with primary breast cancer in April 2010. 
Immunohistochemistry of the primary tumour revealed that the patient had Luminal A breast 
cancer and was positive for oestrogen (ER+) and progesterone (PR+) receptors but are 
negative for HER2(-) receptors. The patient initially declined any systemic treatment and was 
only given radiotherapy. However in August 2014, BRC013 was diagnosed with an axillary 
recurrence of the disease. Then, in August 2016, the patient was eventually diagnosed with 
advanced metastatic breast cancer. Treatment with paclitaxel was then commenced in 
September 2016 and then switched to aromatase inhibitor in February 2017. CT scans from 
May 2017 however revealed that the patient had progressive disease.  
 
The patient was enrolled into the study in June 2017. Targeted NGS of the FFPE DNA 
extracted from the primary tumour specimen of BRC013 identified that the patient had a 
novel TP53 c.560-1G>A mutation. A specific ddPCR assay was designed and optimized with 
a melting temperature of 58.2oC. Results show that the FFPE DNA had 5.66 ± 0.40 copies/µL 
of the TP53 mutation while no mutant copies were detected in the gDNA samples (wild type 
positive control). Levels of ctDNA from 17 cycles of plasma samples collected from June 
2017 to July 2018 were analysed in this study (Figure 3.20).   
 
Analysis of the first cycle revealed that the patient had 244.93 ± 10.64 copies/mL of the TP53 
mutation. The patient then commenced treatment with capecitabine (3rd line of treatment) 
towards the end of June 2017 and then the ctDNA levels started to drop down in cycle 2 
(86.43 ± 17.26 copies/mL). The concentration decreased again in cycle 3 (54.63 ± 4.50 
copies/mL) and cycle 4 (54.33 ± 6.09 copies/mL). The results suggests possible correlation 
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with further scans in September 2017 which showed that the patient was responding to the 
treatment  
 
ctDNA started to rise again from October 2017. However, the patient was still diagnosed with 
a stable disease in December 2017 with no evidence of local recurrence. Levels of ctDNA 
still continued to increase, but the patient was only eventually diagnosed with disease 
progression in February 2018. BRC013 then switched treatments to vinorelbine (4 th line of 
treatment) in March 2018 but the ctDNA levels still increased until the highest concentration 
(23,152.40 ± 814.07 copies/mL) was reached in the cycle 12 of serial plasma collected in 
April 2018. ctDNA soon started to drop down in the following cycles and it was confirmed 
by CT scans in May 2018 that the patient was responding to treatments. The patient ceased 



















Figure 3.20. Concentration (mean copies/mL plasma ± SE) of TP53 c.560-1G>A 
mutation in the ctDNA of serial blood collection cycles from patient BRC013. Levels of 
TP53 mutation detected from the ctDNA of 17 cycles of plasma samples from June 2017 to 
July 2018 were analysed and quantified using ddPCR. The mean mutation copies/mL plasma 
was calculated and plotted with the standard error (SE) as error bars. ctDNA remained at high 
levels throughout the study with the highest peak detected in April 2018. Disease progression 
of BRC013 was possibly detected earlier with ctDNA as the levels started to increase in 
October 2017 while the CT scans were only able to detect the progressive disease in February 
2018. The patient was treated with vinorelbine with response and then ceased blood 








Patient BRC048 was a 38 year-old female diagnosed with metastatic breast cancer with 
multiple bone metastases in June 2015. Histopathological analysis revealed that there was a 
macroscopically visible malignant tumour and a left wide local excision in the breast. 
Immunohistochemistry of the collected primary tumour specimen also showed that the 
patient had Luminal A breast cancer and was positive for oestrogen (ER+) and progesterone 
(PR+) receptors but was negative for HER2 receptors. Thus, the patient was treated with 
palliative radiotherapy to thoracic spine and cervical spine. In July 2015, the treatment was 
then switched to palliative tamoxifen and zoledronate.  
 
CT scans from September 2016 revealed multiple metastatic tumour deposits. In November 
2016, multiple bony metastases and diffuse fatty infiltration of the liver with lesions, 
suspicious for metastases, were observed. Thus, in December 2016, the endocrine treatment 
was altered for disease progression and was changed to palliative radiotherapy until January 
2017. In February 2017, the patient was then treated with added goserelin and letrozole. In 
August 2017, scans revealed a significant increase in the extent of skeletal and liver 
metastases.  
 
In September 2017, the patient was enrolled into the study. Targeted NGS of the FFPE DNA 
extracted from the primary tumour specimen of BRC048 identified that the patient had a 
KRAS c.35G>T mutation. A specific ddPCR assay was previously designed and optimized by 
Donghui Zou with a melting temperature of 60.1oC. Results show that the FFPE DNA had 
7.94 ± 0.53 copies/µL of the KRAS mutation while no mutant copies were detected in the 
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gDNA samples. Levels of ctDNA from 11 cycles of plasma samples collected from 
September 2017 to September 2018 were analysed in this study (Figure 3.21).   
 
Analysis of the first cycle revealed that the patient had 170.39 ± 9.73 copies/mL of the KRAS 
mutation. The levels of ctDNA then dropped down to 47.07 ± 8.29 and 39.47 ±4.89 
copies/mL for cycle 2 and 3 respectively. Then, in October 2017, CT scans showed stable 
appearance of the liver disease and no progressive disease was seen. In November 2017, the 
detected ctDNA concentration continues to decrease in the cycle 4 (5.58 ± 1.87 copies/mL) 
and cycle 5 (4.85 ±1.87 copies/mL). The patient was then given palliative weekly paclitaxel 
chemotherapy, which was later dropped by another 15% given persistent neutropenia, and 
given until December 2017.  
 
ctDNA however started to increase in the cycle 6 (16.25 ± 2.39 copies/mL) collected in 
March 2018 until it reached 346.14 ± 18.36 copies/mL in the cycle 8 of serial plasma samples 
collected in June 2018. Thus, in July 2018, the patient completed another palliative 
radiotherapy to the left shoulder and then the levels of ctDNA slightly decreased to 227.85 ± 
15.52 copies/mL in cycle 9. However, ctDNA soon increased again until the highest 
concentration was reached in the cycle 10 (713.96 ± copies/mL), possibly suggesting disease 
progression. But then, ctDNA slightly decreased again to 338.40 ± 12.70 copies/mL in cycle 
11 and the patient ceased providing blood samples in September 2018.  
 
The patient was only diagnosed with a progressive disease a month later (October 2018) 
when at least 3 necrotic metastases were observed in the patient‟s CT scans. Multiple brain 
metastases and multiple areas of skull with metastases were observed and the patient was also 
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observed with progression of diffuse bony metastases. Thus, the patient was treated with 




Figure 3.21. Concentration (mean copies/mL plasma ± SE) of KRAS c.35G>T mutation 
in the ctDNA of serial blood collection cycles from patient BRC048. Levels of KRAS 
mutation detected from the ctDNA of 11 cycles of plasma samples from September 2017 to 
September 2018 were analysed and quantified using ddPCR. The mean mutation copies/mL 
plasma was calculated and plotted with the standard error (SE) as error bars. Disease 
progression of BRC048 was possibly detected earlier with ctDNA as the levels started to 
increase in April 2018 with the highest concentration detected in August 2018 while the CT 
scans were only able to detect the progressive disease in October 2018. The patient was 








Patient BRC049 was 39 year-old female diagnosed in September 2012 with primary breast 
cancer involving left axillary lymphadenopathy with no further evidence of metastatic 
disease. Immunohistochemistry of the primary tumour revealed that the patient had HER2-
enriched breast cancer and was negative for oestrogen (ER-) and progesterone (PR-) 
receptors, but was positive for HER2 receptors. In October 2012, the patient started treatment 
with neoadjuvant FEC/docetaxel chemotherapy and Herceptin with docetaxel. Further tests 
done in March 2013 revealed left multifocal breast cancer with no discrete well defined 
tumour masses. The patient was then treated with adjuvant radiotherapy in April 2013 and 
was then reported to have no further recurrent or metastatic disease in February 2015. 
 
In April 2016, multiple small pulmonary nodules which were consistent with metastatic 
disease were observed in CT scans. The patient was thereby treated with port insertion and 
palliative chemotherapy while maintenance Herceptin was continued. Further tests in July 
2016 revealed metastases similar to previous but appeared less prominent with no new 
evidence of metastasis. In October 2016, stable appearance was observed for small 
pulmonary nodules and no new metastatic disease was seen. Moreover, CT scans in February 
2017 showed that the previously seen small lung opacities had become stable.  
 
In August 2017, there was a significant increase in number and size of known metastatic lung 
nodules, highly suggestive of disease progression. The patient was then treated with 
gemcitabine with Herceptin; however gemcitabine was stopped after one cycle due to 
toxicity. The patient was then recruited into the study in September 2017.  
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Targeted NGS of the FFPE DNA extracted from the primary tumour specimen of BRC049 
identified that the patient had a PIK3CA c.1034A>G mutation. A specific ddPCR assay was 
previously designed and optimized by S. Parackal with a melting temperature of 58.2oC. 
Results show that the FFPE DNA had 2.88 ± 0.20 copies/µL of the PIK3CA mutation while 
no mutant copies were detected in the gDNA samples. Levels of ctDNA from 12 cycles of 
plasma samples collected from September 2017 to December 2018 were analysed in this 
study (Figure 3.22).   
 
Analysis of the first cycle collected in September 2017 revealed that the patient had 8.67 ± 
1.35 copies/mL of the PIK3CA mutation. The patient continued to have low levels of ctDNA 
in cycle 2 (8.71 ± 2.56 copies/mL) and cycle 3 (6.20 ±1.20 copies/mL), but then towards the 
end of November 2017, ctDNA started to slowly increase in cycle 4. CT scans then revealed 
that the patient was diagnosed with progressing lung metastases on single agent Herceptin.  
 
Levels of ctDNA then continued to increase until the highest concentration was reached in 
cycle 8 (27.86 ± 4.75 copies/mL) collected in March 2018. The patient ceased collection in 
July 2018, but further tests in August 2018 revealed that the patient had progressive 
metastatic disease in both lungs but there was no suspicious metastatic disease in liver/bones. 
The patient was then treated with single agent capecitabine, but in September and October 
2018, CT scans still showed pulmonary progression. Thus, one last cycle of blood sample 
was collected in December 2018 and 14.16 ± 4.20 copies/mL of the PIK3CA mutation was 











Figure 3.22. Concentration (mean copies/mL plasma ± SE) of PIK3CA c.1034A>G 
mutation in the ctDNA of serial blood collection cycles from patient BRC049. Levels of 
PIK3CA mutation detected from the ctDNA of 12 cycles of plasma samples from September 
2017 to December 2018 were analysed and quantified using ddPCR. The mean mutation 
copies/mL plasma was calculated and plotted with the standard error (SE) as error bars. 
Although low levels of ctDNA were detected in all the cycles available for analysis, the 
fluctuations in the concentration of ctDNA suggest potential correlation with the tumour 








Patient BRC050 was a 58 year-old female diagnosed with breast cancer involving an invasive 
tumour in September 2014. Immunohistochemistry of the primary tumour revealed that the 
patient had TNBC and was negative for oestrogen (ER-), progesterone (PR-) and HER2 
receptors. In August 2017, the patient was diagnosed with an extensive metastatic tumour and 
was then enrolled into the study.  
 
Targeted NGS of the FFPE DNA extracted from the primary tumour specimen of BRC050 
determined that the patient had a TP53 c.939delA mutation (previously identified by S. 
Parackal). A specific ddPCR assay was designed and optimized in this study with a melting 
temperature of 58.2oC. Results show that the FFPE DNA had 41.11 ± 1.38 copies/µL of the 
TP53 mutation while no mutant copies were detected in the gDNA samples (wild type 
positive control). Levels of ctDNA from 3 cycles of plasma samples collected from August 
2017 to October 2017 were analysed (Figure 3.23).   
 
The highest concentration of ctDNA (1941.86 ± 67.22 copies/mL) was detected in the first 
cycle. The patient was then treated with palliative gemicitabine chemotherapy in September 
2017 and the levels of ctDNA soon decreased to 1086.92 ± 30.43 copies/mL in the 2nd cycle. 
In October 2017, ctDNA further dropped down to 866.59 ±5.11 copies/mL in cycle 3 and the 
patient was then withdrawn from the study after only three cycles of blood collection.  
 
CT scans done towards the end of October 2017 showed that the patient had continued left 
lung and pleural metastatic disease with progression. Thus, palliative gemicitabine 
chemotherapy was stopped and the patient instead completed palliative radiotherapy. 
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BRC050 was clinically observed to be significantly better after the treatment. Unfortunately, 
there are no more patient samples available to verify whether the ctDNA levels still correlate 




Figure 3.23. Concentration (mean copies/mL plasma ± SE) of TP53 c.939delA mutation 
in the ctDNA of serial blood collection cycles from patient BRC050. Levels of TP53 
mutation detected from the ctDNA of 3 cycles of plasma samples from August to October 
2017 were analysed and quantified using ddPCR. The mean mutation copies/mL plasma was 
calculated and plotted with the standard error (SE) as error bars. ctDNA was detected at high 
levels in all the available cycles for analysis with the highest peak detected in the first cycle 
(August 2017). The results suggest potential correlation with CT scans which revealed that 








Patient BRC052 was diagnosed with primary breast cancer in August 2007. 
Immunohistochemistry of the primary tumour revealed that the patient had Luminal B breast 
cancer and was positive for oestrogen (ER+), progesterone (PR+) and HER2 receptors. In 
September 2017, a new FFPE specimen was collected and the patient was found to have right 
breast carcinoma with family history of breast cancer. In October 2017, the patient was 
diagnosed with metastatic breast cancer. The patient then started 1st line of treatment with 
THP (Taxotere/docetaxel, Herceptin/trastuzumab and pertuzumab) and was recruited to the 
study in December 2017.  
 
All the clinical samples of BRC052 were previously analysed by S. Parackal. The results are 
then included in the thesis to provide a more comprehensive report. Targeted NGS of the 
FFPE DNA extracted from the primary tumour specimen of BRC052 identified that the 
patient had a TP53 c.592G>T mutation. A specific ddPCR assay was designed and optimized 
with a melting temperature of 54.1oC. Results show that the FFPE DNA had 3.89 copies/µL 
of the TP53 mutation while no mutant copies were detected in the gDNA samples. 
 
Levels of ctDNA from 4 cycles of plasma samples collected from December 2017 to 
February 2018 were analysed (Figure 3.24). The highest concentration of ctDNA (4003.02 ± 
32.18 copies/mL) was detected in the first cycle collected in September 2017. Levels of 
ctDNA then started to slightly decrease in cycle 2 (1149.61 ± 18.36 copies/mL) and cycle 3 
(949.06 ± 34.46 copies/mL), but in the cycle 4 collected in February 2018, the ctDNA 
increased again to 2548.66 ± 30.18 copies/mL of the TP53 mutation.  
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The results suggests possible correlation with CT scans which revealed a significant 
progression and new metastases. However, the patient was withdrawn from the study after 
only 4 cycles of blood collection. Further tests in March 2018 revealed similar appearances to 
widespread osseous metastases. Thus, the patient started treatment with capecitabine (2nd line 
of treatment). Unfortunately, there are no more patient samples available to verify whether 
the ctDNA levels still correlate with the disease progression of BRC052.  
 
 
Figure 3.24. Concentration (mean copies/mL plasma ± SE) of TP53 c.592G>T mutation 
in the ctDNA of serial blood collection cycles from patient BRC052. Levels of TP53 
mutation detected from the ctDNA of 4 cycles of plasma samples from December 2017 to 
February 2018 were analysed and quantified using ddPCR. The mean mutation copies/mL 
plasma was calculated and plotted with the standard error (SE) as error bars. ctDNA was 
detected at high levels in all the available cycles for analysis with the highest peak detected in 
the first cycle (December 2017). The results suggest potential correlation with CT scans 






Patient BRC090 was a 57 year-old female diagnosed with metastatic carcinoma in March 
2013. Immunohistochemistry of the primary tumour revealed that the patient had HER2-
enriched breast cancer and was positive for HER2 receptors but was negative for oestrogen 
(ER-) and progesterone (PR-) receptors. The patient was then treated with adjuvant FEC 
docetaxel until August 2013 and adjuvant chemotherapy until September 2013. The patient 
was given adjuvant Herceptin and then completed treatment in May 2014.  
 
In April 2017, the patient was diagnosed with metastatic breast cancer with FNA (fine-needle 
aspiration biopsy) proven supraclavicular disease. Further tests in July 2017 revealed lymph 
node and probable pulmonary metastases. The patient was treated with palliative docetaxel 
with trastuzumab & pertuzumab and then enrolled into the study in October 2017.  
 
Targeted NGS of the FFPE DNA extracted from the primary tumour specimen of BRC090 
identified that the patient had a PIK3CA c.3140A>G mutation. A specific ddPCR assay was 
designed and optimized with a melting temperature of 56.0oC. Results show that the FFPE 
DNA had 4.06 ± 0.42 copies/µL of the PIK3CA mutation while no mutant copies were 
detected in the gDNA samples (wild type positive control). Levels of ctDNA from 10 cycles 
of plasma samples collected from October 2017 to September 2018 were analysed (Figure 
3.25).  
 
Low levels of ctDNA (<4.0 copies/mL) were detected in all available cycles of plasma 
samples throughout the study. The results suggest possible correlation with CT scans, which 
showed that the patient remained very well and unremarkable in November 2017. Plasma 
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samples were continuously collected from the patient and then in October 2018, the patient 
has ceased blood collection but has not progressed.  
 
However, only a month later (November 2018), CT scans revealed that the patient had 
progressive disease involving the enlargement of right mid lobe. Unfortunately, there are no 
more patient samples available to verify whether the ctDNA levels still correlate with the 
disease progression of BRC090. 
 
 
Figure 3.25. Concentration (mean copies/mL plasma ± SE) of PIK3CA c.3140A>G 
mutation in the ctDNA of serial blood collection cycles from patient BRC090. Levels of 
PIK3CA mutation detected from the ctDNA of 10 cycles of plasma samples from October 
2017 to September 2018 were analysed and quantified using ddPCR. The mean mutation 
copies/mL plasma was calculated and plotted with the standard error (SE) as error bars. Low 
levels of ctDNA were detected in all the available cycles of plasma samples and the patient 








Patient BRC092 was a 51 year-old female diagnosed with an invasive breast carcinoma in 
October 2017. Immunohistochemistry of the primary tumour revealed that the patient had 
HER2-enriched breast cancer and was positive for HER2 receptors but was negative for 
oestrogen (ER-) and progesterone (PR-) receptors. Further tests in November 2017 show that 
the primary tumour found in the right breast had multiple liver metastases. In December 
2017, CT scans revealed a smaller breast tumour and was then enrolled into the study.  
 
Targeted NGS of the FFPE DNA extracted from the primary tumour specimen of BRC090 
identified that the patient had a TP53 c.584T>C mutation. A specific ddPCR assay was 
designed and optimized with a melting temperature of 58.2oC. Results show that the FFPE 
DNA had 5.22 ± 0.10 copies/µL of the TP53 mutation while no mutant copies were detected 
in the gDNA samples (wild type positive control). Levels of ctDNA from 11 cycles of plasma 
samples collected from December 2017 to August 2018 were analysed (Figure 3.26).  
 
Low levels of ctDNA (<3.0 copies/mL) were detected in all available cycles of plasma 
samples throughout the study. The patient started treatment with palliative docetaxel, 
Herceptin & pertuzumab and then has ceased collection of blood samples in October 2018 












Figure 3.26. Concentration (mean copies/mL plasma ± SE) of TP53 c.584T>C mutation 
in the ctDNA of serial blood collection cycles from patient BRC092. Levels of TP53 
mutation detected from the ctDNA of 11 cycles of plasma samples from December 2017 to 
August 2018 were analysed and quantified using ddPCR. The mean mutation copies/mL 
plasma was calculated and plotted with the standard error (SE) as error bars. Low levels of 
ctDNA were detected in all the available cycles of plasma samples and the patient remained 









Patient BRC095 was diagnosed with primary breast cancer in March 2016. 
Immunohistochemistry of the primary tumour revealed that the patient was initially positive 
for HER2 (+) receptors but was negative for oestrogen (ER-) and progesterone (PR-) 
receptors. In August 2018, the patient underwent her first CT scan and was then diagnosed 
with metastatic breast carcinoma and another FFPE specimen was collected. Further tests 
eventually revealed that the patient had Luminal B breast cancer and tested positive for all 
ER (+), PR (+) and HER2 (+) receptors.  
 
In September 2018, the patient was enrolled into the study. Targeted NGS of the FFPE DNA 
extracted from the primary tumour specimen of BRC095 identified that the patient had 
PIK3CA c.1633G>A and TP53 c.636delT mutation. Specific ddPCR assays were designed 
and optimized with a melting temperature of 60.1oC and 58.2oC for the PIK3CA and TP53 
assay respectively. Results show that the FFPE DNA had 11.84 ± 0.79 copies/µL of the 
PIK3CA mutation. However, since there were only limited amount of DNA extracted from 
the available tissue sample of BRC095, it was not possible to test the TP53 assay on the 
FFPE DNA. No mutant copies were detected in the gDNA samples. Levels of ctDNA from 
10 cycles of plasma samples collected from September 2018 to November 2019 were 
analysed (Figure 3.27).  
 
Analysis of the first cycle revealed the highest ctDNA concentration for both the PIK3CA 
(107.86 ± 7.07 copies/mL) and TP53 (115.08 ± 6.85 copies/mL) assay throughout the study. 
The patient then started treatment with vinorelbine, pertuzumab and Herceptin (1st line of 
treatment) and the ctDNA immediately dropped down to lower levels (<10.0 copies/mL) in 
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the subsequent cycles for both assays. The results from the ctDNA analysis suggests possible 
correlation with CT scans which revealed that in December 2018 and April 2019, the patient 
was responding to the treatment. In May 2019, the patient was treated with capecitabine and 
then in August 2019, CT scans revealed that the patient has a stable disease. The patient 
ceased blood collection in September 2019 but has not clinically progressed. No further 
clinical information was acquired for patient BRC095. 
 
 
Figure 3.27. Concentration (mean copies/mL plasma ± SE) of PIK3CA c.1633G>A and 
TP53 c.636delT mutation in the ctDNA of serial blood collection cycles from patient 
BRC095. Levels of PIK3CA and TP53 mutation detected from the ctDNA of 10 cycles of 
plasma samples from September 2018 to November 2019 were analysed and quantified using 
ddPCR. The mean mutation copies/mL plasma was calculated and plotted with the standard 
error (SE) as error bars. The highest ctDNA concentration was detected in the first cycle for 
both PIK3CA and TP53 mutation assay. Low levels of ctDNA were detected in the following 





Overall, this study investigated metastatic breast cancer patients with diverse molecular 
subtypes that have distinct behaviours and responses to therapy based on the expression of 
several clusters of genes relating to oestrogen receptor (ER), progesterone receptor (PR), and 
human epidermal growth factor 2 (HER2) proteins which contribute to the growth and 
function of breast cells (Feng et al., 2018; Dawson et al., 2013; Smith et al., 2019).  
 
The patients were composed mainly of Luminal B (33%) breast cancers that are usually 
treated with chemotherapy or hormone therapy. The other 28% of the patients were mainly 
composed of Luminal A breast cancer patients who have a low-grade, slow growing subtype 
that has a slightly better prognosis than Luminal B and is typically treated with chemotherapy 
and hormonal therapy targeted to HER2. Another set of patients (28%) were classified as the 
HER2-enriched subtype, who are likely to benefit from chemotherapy and can be 
successfully treated with targeted therapies aimed at HER2. The remaining 11% had a more 
aggressive TNBC subtype whose treatment is usually limited only to conventional 
chemotherapy (Feng et al., 2018).  
 
However, although the characterization of the molecular subtypes from tumour tissue 
analysis has become the standard, tumour heterogeneity is still one of the hallmarks of breast 
cancer. Therefore, this study investigated the detection of ctDNA using ddPCR to enable the 
non-invasive assessment of the patients‟ entire disease burden. Genomic characterization of 
ctDNA can potentially circumvent the problem that tumour heterogeneity poses to the 
analysis of the primary tumour and since the half-life of the ctDNA that can be detected in 
plasma is limited to only 16-150mins, it can serve as a potential biomarker for the real time 
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and accurate surveillance of tumour mutation dynamics throughout the course of the disease 
(Rosell & Karachaliou, 2016; Zhou et al., 2019; Diehl et al., 2008) 
 
Among the 18 BRC patients with working assays, only 2 patients (BRC008, BRC010) had 
undetectable ctDNA and had no evidence of disease progression throughout serial plasma 
sample collection. Overall, the results of the study was found to be in line with the findings of 
recent reports using similar methods (Dawson et al, 2013; Olsson et al., 2015). ctDNA 
detected using personalized ddPCR assays showed dynamic changes in the tumour burden of 
16/18 (89%) patients with fluctuations in the levels of ctDNA across serial plasma samples 
suggesting possible correlation with the available clinical information for each metastatic 
breast cancer patients. Among the 16 breast cancer patients with positive ctDNA levels for 
one or more follow up plasma samples, six patients (BRC004, BRC005, BRC012, BRC049, 
BRC090, and BRC092) were observed to have low levels of ctDNA (<30 copies/mL plasma). 
These patients were observed to have a low burden of metastatic disease or were eventually 
diagnosed to have stable disease during the study. The remaining 10/16 patients (BRC001, 
BRC002, BRC006, BRC007, BRC009, BRC013, BRC048, BRC050, BRC052, and BRC095) 
were observed to have high levels of ctDNA, possibly suggesting disease progression. 
Results thereby suggest that the ctDNA levels can correlate with tumour burden and be 
quantitatively predictive of the response to administered treatments and overall clinical 
outcome.  
 
The metastatic breast cancer patients observed in the study had multiple metastases primarily 
in bones (40%), liver (20%), lungs (20%), lymph nodes (10%), pancreas (3.33%), stomach 
(3.33%), and chest wall (3.33%). Similar to the results of a study by Rosell & Karachaliou 
(2016), higher levels of ctDNA were mostly observed in patients with metastasis to the liver 
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(BRC001, BRC006, BRC009, BRC013, and BRC048) compared to those metastases to other 
organs. Patients with metastasis to the lymph nodes (BRC090), lungs (BRC005, BRC012, 
BRC049) and bones (BRC004, BRC008, BRC010) usually have low levels of ctDNA.  
 
Furthermore, progressive disease was documented on radiographic imaging in 14 out of 18 
BRC patients. Results of the ctDNA analysis suggests that the increase in the concentration 
of ctDNA possibly reflected progressive disease in 12/14 BRC patients diagnosed with 
disease progression throughout the study. Increasing ctDNA levels were not observed in the 
other two patients (BRC010 and BRC090) since several cycles of blood collection were 
missed and unfortunately, there were no samples available to verify whether ctDNA 
potentially correlated with the disease progression. Furthermore, for patient BRC002 in 
particular, although there was an eventual increase in the ctDNA levels, disease progression 
was detected  two months later than CT imaging scans since cycles of blood collection were 
missed and no plasma samples were able to be collected.  
 
However, in some cases, results suggests that ctDNA provided an earlier assessment of 
response to administered treatments in 11 out of 18 women (56%), which is consistent with 
recent studies of ctDNA in other solid cancers (Dawson et al, 2013; Olsson et al., 2015). In 
particular, ctDNA detection were observed to have preceded the clinical diagnosis of disease 
progression in 5/11 patients (BRC005, BRC012, BRC013, BRC048, and BRC049) with an 
average lead time of 109 days (range 6-265 days) earlier than scheduled CT imaging. On the 
other hand, the levels of ctDNA detected in 9 out of 11 of these patients (BRC001, BRC002, 
BRC005, BRC006, BRC007, BRC012, BRC013, BRC090, and BRC095) were observed to 
reflect stable disease or positive response to treatment with an average lead time of 48 days 







CTDNA ANALYSIS OF COLORECTAL CANCER 
 
STUDY DESIGN 
This sub-study is a part of a larger CRC project in our laboratory funded by Healthier Lives, 
which has utilised a similar protocol described in the breast cancer project through the 
targeted NGS of archived primary tumours DNA to enable the design of highly sensitive and 
specific ddPCR mutation assays to routinely monitor the ctDNA levels in 60 patients from 
Dunedin, New Zealand with advanced CRC.  
 
The current ddPCR method described in the previous study can only assess one mutation at a 
time. However, as noted earlier, due to tumour heterogeneity and the ability of tumours to 
obtain new genomic alterations throughout the course of their treatment, a single mutation 
marker may not be enough to accurately assess the response of patients to drug treatment. In 
a single mutation assay, the monitored predominant tumour clone might be reduced upon 
treatments but heterogeneous regions of the tumours may have proliferated.  
 
Thus, in order to explore tumour heterogeneity and help reduce the risk of unnoticed 
proliferation, a multiplexing ddPCR method was investigated to allow the simultaneous 
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detection of two previously identified tumour-specific mutation markers in a single tumour 
FFPE DNA and/or ctDNA sample from selected patients from New Zealand undergoing 
systemic therapy for advanced metastatic colorectal cancer.  
 
OPTIMIZATION OF MULTIPLEX DDPCR ASSAYS 
In this study, the primer and probe concentration of personalized mutation assays were 
initially optimized to target multiple genomic alterations for the ddPCR analysis of the FFPE 
DNA isolated from seven advanced metastatic colorectal cancer patients. The optimal 
melting temperature (Tm) was then determined using gradient ddPCR with Human Genomic 
DNA [Roche, Switzerland] utilised as the wild-type positive control. Shown in Table 4.1 are 
the tumour-specific mutations previously identified by Donghui Zou and Robert Day for each 
patient with their optimized Tm. To maintain anonymity, each patient was referred to by their 
study ID. 
 
Sample Assay 1 Tm Assay 2 Tm 
M009 TP53 c.524 G>A 60.1 KRAS c.35 G>A 60.3 
M014 APC c.3203 C>G 56.0 TP53 c.794 T>A 56.0 
M018 BRAF c.1799 T>A 58.2 TP53 c.586 C>T 56.0 
M019 TP53 c.818 G>A 58.2 BRAF c.1799 T>A 58.2 
M031 TP53 c.818 G>A 58.2 KRAS c.35 G>A 60.3 
M040 TP53 c.524 G>A 60.1 KRAS c.35 G>T 60.1 
M048 TP53 c.817 C>T 58.2 BRAF c.1799 T>A 58.2 
 
Table 4.1. Tumour-specific mutation assays previously identified for the multiplex ddPCR of 
selected colorectal cancer (CRC) patients with their optimized Tm. 
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Shown in Figure 4.1 is an optimized multiplex ddPCR mutation assay with robust and 
distinct droplet signals from two ideally separated fluorescence amplitude bands detected in a 
single ddPCR reaction. Each multiplex ddPCR assay was run with at least 3 replicates and 
included wild-type positive (normal genomic DNA) and negative (RNAse-free water) 
controls in order to define „rain partitions‟ that should be excluded from the analysis. The 
multiplex ddPCR run is then further analysed using QuantaSoft Analysis Pro Software [Bio-
Rad, USA] and the threshold of the optimized assay was then manually set to differentiate 
between the two different clusters of mutant droplets detected by ddPCR software and 
determine any false-positives and false-negatives. 
 
 
Figure 4.1. Optimized 1D (right) and 2D (left) plot of droplet fluorescence obtained 
from a multiplex ddPCR run. As observed in the 1D plot, the blue droplets are the mutant 
type, whilst the green are the wild type droplets. The grey droplets represent the background 
droplets that are neither mutant nor wild type. The 1D plot shows two ideally separated 
fluorescence amplitude bands of tumour-specific gene mutation assays in a single ddPCR 
reaction.  The 2D plot was generated from QuantaSoft Analysis Pro Software [Bio-Rad, 
USA] in order to assign different coloured droplets and differentiate the two different 







Primer and probe concentration for both KRAS c.35G>A and TP53 c.524G>A assays were 
optimized, as shown in Table 4.2, in the FFPE DNA isolated from patient M009 for a 
multiplex ddPCR assay. The optimized multiplex assay (Figure 4.2) shows well separated 
amplitude bands and distinct clusters of mutant droplets upon increasing the primer and 
mutant probe concentration of the KRAS assay. Since the wild type droplets were harder to 
separate, the concentration of the KRAS wild type probe were optimized to be three times 
higher than that of the TP53 assay in order to obtain separated fluorescence bands, enough to 
distinguish between the assays.  
 
Further tests revealed that there would be a more distinct separation between the clusters of 
mutant and wild type droplets upon running the samples at 58.2oC rather than the previously 
optimized Tm of 60.1
oC from gradient PCR. The optimized multiplex ddPCR assay for M009 
was also compared to the corresponding single mutation assays (Figure 4.3) in order to check 
if the assays can effectively detect both the KRAS and TP53 mutation with the same accuracy.  
 
Upon analysis of the obtained mutant and wild type droplet concentration from the generated 
assays, it can be observed in Figure 4.4 that there is a comparable mean concentration 
(copies/µL ± SEM) detected from multiplex ddPCR and single mutation ddPCR assays. In 
particular, the multiplex ddPCR assay detected 11.84 ± 0.36 and 27.62 ± 0.75 copies/µL of 
the KRAS and TP53 mutation respectively, while the single mutation ddPCR assay detected 









 Assay 1 Assay 2 Assay 3 
Mastermix 11 11 11 
KRAS Primer Forward 0.77 - 0.77 
Reverse 0.77 - 0.77 
KRAS Probe Mutant Type 0.50 - 0.50 
Wild Type 0.99 - 0.99 
TP53 Primer Forward - 0.66 0.66 
Reverse - 0.66 0.66 
TP53 Probe Mutant Type - 0.30 0.30 
Wild Type - 0.33 0.33 
Water  1.97 3.05 0.02 
Sample (M009) 6 6 6 
TOTAL 22 22 22 
Table 4.2. Volume (µL) of reagents used for KRAS c.35G>A and TP53 c.524G>A single 
mutation (Assay 1 & 2) and multiplex (Assay 3) ddPCR assays for the FFPE DNA of patient 











Multiplex ddPCR assay (Assay 3) 
(a)
(b)  
Figure 4.2. 1D (a) and 2D (b) plot of droplet fluorescence detected from KRAS c.35G>A and 












Single mutation ddPCR assay (Assay 1 & 2) 
(a)   
(b)
Figure 4.3.  1D (a) and 2D (b) plot of droplet fluorescence detected from KRAS c.35G>A and 
TP53 c.524G>A single mutation ddPCR assays (Assay 1 & 2) for the FFPE DNA (1ng/µL) 














Figure 4.4. Comparison of mean (± SEM) mutant and wild type droplet concentration 
(copies/µL) detected for KRAS c.35G>A and TP53 c.524G>A single mutation (Assay 1 & 2) 
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Primer and probe concentration for both APC c.3203C>G and TP53 c.794T>A assays were 
optimized, as shown in Table 4.3, in the FFPE DNA isolated from patient M014 for a 
multiplex ddPCR assay. The optimized multiplex assay (Figure 4.5) shows well separated 
amplitude bands and distinct clusters of mutant and wild type droplets upon increasing both 
the primer and probe concentration of the APC assay to three times higher than that of the 
TP53 assay. Further tests revealed that a more distinct separation between the clusters of 
mutant and wild type droplets could be achieved upon running the samples at 54oC rather 
than the previously optimized Tm of 56
oC from gradient PCR.  
 
The optimized multiplex ddPCR assay for M014 was also compared to the corresponding 
single mutation assays (Figure 4.6) in order to check if the assays can effectively detect both 
the APC and TP53 mutation with the same accuracy. Upon analysis of the obtained mutant 
and wild type droplet concentration from the generated assays, it can be observed in Figure 
4.7 that there is a comparable mean concentration (copies/µL ± SEM) detected from 
multiplex ddPCR and single mutation ddPCR assays. In particular, the multiplex ddPCR 
assay detected 19.78 ± 0.47 and 45.58 ± 1.46 copies/µL of the APC and TP53 mutation 
respectively, while the single mutation ddPCR assay detected 24.45 ± 0.53 and 49.19 ± 1.25 









 Assay 1 Assay 2 Assay 3 
Mastermix 11 11 11 
APC Primer Forward 0.99 - 0.99 
Reverse 0.99 - 0.99 
APC Probe Mutant Type 0.66 - 0.66 
Wild Type 0.825 - 0.825 
TP53 Primer Forward - 0.33 0.33 
Reverse - 0.33 0.33 
TP53 Probe Mutant Type - 0.22 0.22 
Wild Type - 0.275 0.275 
Water  1.535 3.845 0.38 
Sample (M014) 6 6 6 
TOTAL 22 22 22 
Table 4.3. Volume (µL) of reagents used for APC c.3203C>G and TP53 c.794T>A single 
mutation (Assay 1 & 2) and multiplex (Assay 3) ddPCR assays for the FFPE DNA of patient 












Multiplex ddPCR assay (Assay 3) 
(a)
(b)
Figure 4.5. 1D (a) and 2D (b) plot of droplet fluorescence detected from APC c.3203C>G 












Single mutation ddPCR assay (Assay 1 & 2) 
(a)
(b)
Figure 4.6. 1D (a) and 2D (b) plot of droplet fluorescence detected from APC c.3203C>G 
and TP53 c.794T>A single mutation ddPCR assays (Assay 1 & 2) for the FFPE DNA 














Figure 4.7. Comparison of mean (± SEM) mutant and wild type droplet concentration 
(copies/µL) detected for APC c.3203C>G and TP53 c.794T>A single mutation (Assay 1 & 2) 
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Primer and probe concentration for both BRAF c.1799T>A and TP53 c.586C>T assays were 
optimized, as shown in Table 4.4, in the FFPE DNA isolated from patient M018 for a 
multiplex ddPCR assay. Since a commercially manufactured TP53 assay [Bio-Rad, USA] 
was used, this multiplex assay was more difficult to optimize compared to other patient 
samples.  However, upon increasing both the primer and probe concentration of the BRAF 
assay, the optimized multiplex assay (Figure 4.8) shows well separated amplitude bands and 
distinct clusters of mutant and wild type droplets.  
 
Further tests revealed that a more distinct separation between the clusters of mutant and wild 
type droplets could be achieved upon the dilution of the FFPE DNA (1ng/µL) to 1:5 and 
running the samples at 58.2oC rather than the previously optimized Tm for the TP53 assay 
(56.0oC) from gradient PCR. The optimized multiplex ddPCR assay for M018 was also 
compared to the corresponding single mutation assays (Figure 4.9) in order to check if the 
assays can effectively detect both the BRAF and TP53 mutation with the same accuracy. It 
can be observed in Figure 4.10 that there is a comparable mean concentration (copies/µL ± 
SEM) detected from multiplex ddPCR and single mutation ddPCR assays. In particular, the 
multiplex ddPCR assay detected 13.74 ± 2.27 and 11.10 ± 1.00 copies/µL of the BRAF and 
TP53 mutation respectively, while the single mutation ddPCR assay detected 17.02 ± 0.67 









 Assay 1 Assay 2 Assay 3 
Mastermix 11 11 11 
BRAF Primer Forward 0.77 - 0.77 
Reverse 0.77 - 0.77 
BRAF Probe Mutant Type 0.66 - 0.66 
Wild Type 0.66 - 0.66 
TP53 Primer Forward - 
1.1 1.1 
Reverse - 
TP53 Probe Mutant Type - 
Wild Type - 
Water  2.14 3.90 1.04 
Sample (M018) 6 6 6 
TOTAL 22 22 22 
Table 4.4. Volume (µL) of reagents used for BRAF c.1799T>A and TP53 c.586C>T single 
mutation (Assay 1 & 2) and multiplex (Assay 3) ddPCR assays for the FFPE DNA of patient 












Multiplex ddPCR assay (Assay 3) 
(a)
(b)
Figure 4.8. 1D (a) and 2D (b) plot of droplet fluorescence detected from BRAF c.1799T>A 
and TP53 c.586C>T multiplex ddPCR assay (Assay 3) for the FFPE DNA (1ng/µL) of 











Single mutation ddPCR assay (Assay 1 & 2) 
(a)
(b)
Figure 4.9. 1D (a) and 2D (b) plot of droplet fluorescence detected from BRAF c.1799T>A 
and TP53 c.586C>T single mutation ddPCR assays (Assay 1 & 2) for the FFPE DNA 














Figure 4.10. Comparison of mean (± SEM) mutant and wild type droplet concentration 
(copies/µL) detected for BRAF c.1799T>A and TP53 c.586C>T single mutation (Assay 1 & 
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Primer and probe concentration for both BRAF c.1799T>A and TP53 c.818G>A assays were 
optimized, as shown in Table 4.5, in the FFPE DNA isolated from patient M019 for a 
multiplex ddPCR assay. The optimized multiplex assay (Figure 4.11) shows well separated 
amplitude bands and distinct clusters of mutant droplets upon increasing the primer 
concentration of the BRAF assay. However, since the mutant and wild type droplets were 
observed to be more difficult to separate compared to the other multiplex assays, the 
concentration of the BRAF probes were optimized to be two times higher than that of the 
TP53 assay in order to obtain separated fluorescence bands enough to distinguish between the 
assays. Further tests revealed that distinct separation between the clusters of mutant and wild 
type droplets could be achieved upon running the samples at the previously optimized Tm 
58.2oC from gradient PCR.  
 
The optimized multiplex ddPCR assay for M019 was also compared to the corresponding 
single mutation assays (Figure 4.12) in order to check if the assays can effectively detect both 
the BRAF and TP53 mutation with the same accuracy. Upon analysis of the obtained mutant 
and wild type droplet concentration from the generated assays, it can be observed in Figure 
4.13 that there is a comparable mean concentration (copies/µL ± SEM) detected from 
multiplex ddPCR and single mutation ddPCR assays.  In particular, the multiplex ddPCR 
assay detected 37.98 ± 0.79 and 34.69 ± 0.87 copies/µL of the BRAF and TP53 mutation 
respectively, while the single mutation ddPCR assay detected 42.62 ± 0.90 and 35.17 ± 0.83 








 Assay 1 Assay 2 Assay 3 
Mastermix 11 11 11 
BRAF Primer Forward 0.77 - 0.77 
Reverse 0.77 - 0.77 
BRAF Probe Mutant Type 0.55 - 0.55 
Wild Type 0.55 - 0.55 
TP53 Primer Forward - 0.66 0.66 
Reverse - 0.66 0.66 
TP53 Probe Mutant Type - 0.275 0.275 
Wild Type - 0.275 0.275 
Water  2.36 3.13 0.49 
Sample (M019) 6 6 6 
TOTAL 22 22 22 
Table 4.5. Volume (µL) of reagents used for BRAF c.1799T>A and TP53 c.818G>A single 
mutation (Assay 1 & 2) and multiplex (Assay 3) ddPCR assays for the FFPE DNA of patient 













Multiplex ddPCR assay (Assay 3) 
(a)
(b)
Figure 4.11. 1D (a) and 2D (b) plot of droplet fluorescence detected from BRAF c.1799T>A 














Single mutation ddPCR assay (Assay 1 & 2) 
(a)
(b)
Figure 4.12. 1D (a) and 2D (b) plot of droplet fluorescence detected from BRAF c.1799T>A 
and TP53 c.818G>A single mutation ddPCR assays (Assay 1 & 2) for the FFPE DNA 















Figure 4.13. Comparison of mean (± SEM) mutant and wild type droplet concentration 
(copies/µL) detected for BRAF c.1799T>A and TP53 c.818G>A single mutation (Assay 1 & 
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Primer and probe concentration for both KRAS c.35G>A and TP53 c.818G>A assays were 
optimized, as shown in Table 4.6, in the FFPE DNA isolated from patient M031 for a 
multiplex ddPCR assay. The optimized multiplex assay (Figure 4.14) shows well separated 
amplitude bands and distinct clusters of mutant droplets upon increasing the primer and 
mutant probe concentration of the KRAS assay. However, since the wild type droplets were 
observed to be harder to separate, the concentration of the KRAS wild type probe were 
therefore optimized to be three times higher than that of the TP53 assay in order to obtain 
separated fluorescence bands enough to distinguish between the assays. 
 
More distinct separation between the clusters of mutant and wild type droplets was achieved 
upon running the samples at 58.2oC rather than the previously optimized Tm for the KRAS 
assay (60.3oC) from gradient PCR. The optimized multiplex ddPCR assay for M031 was also 
compared to the corresponding single mutation assays (Figure 4.15) in order to check if the 
assays can effectively detect both the KRAS and TP53 mutation with the same accuracy.  
 
Upon analysis of the obtained mutant and wild type droplet concentration from the generated 
assays, it can be observed in Figure 4.16 that there is a comparable mean concentration 
(copies/µL ± SEM) detected from multiplex ddPCR and single mutation ddPCR assays. In 
particular, the multiplex ddPCR assay detected 18.75 ± 0.54 and 17.36 ± 0.96 copies/µL of 
the KRAS and TP53 mutation respectively, while the single mutation ddPCR assay detected 








 Assay 1 Assay 2 Assay 3 
Mastermix 11 11 11 
KRAS Primer Forward 0.77 - 0.77 
Reverse 0.77 - 0.77 
KRAS Probe Mutant Type 0.50 - 0.50 
Wild Type 0.99 - 0.99 
TP53 Primer Forward - 0.66 0.66 
Reverse - 0.66 0.66 
TP53 Probe Mutant Type - 0.30 0.30 
Wild Type - 0.33 0.33 
Water  1.97 3.05 0.02 
Sample (M031) 6 6 6 
TOTAL 22 22 22 
Table 4.6. Volume (µL) of reagents used for KRAS c.35G>A and TP53 c.818G>A single 
mutation (Assay 1 & 2) and multiplex (Assay 3) ddPCR assays for the FFPE DNA of patient 












Multiplex ddPCR assay (Assay 3) 
(a)
(b)
Figure 4.14. 1D (a) and 2D (b) plot of droplet fluorescence detected from KRAS c.35G>A 












Single mutation ddPCR assay (Assay 1 & 2) 
(a)
(b)
Figure 4.15. 1D (a) and 2D (b) plot of droplet fluorescence detected from KRAS c.35G>A 
and TP53 c.818G>A single mutation ddPCR assays (Assay 1 & 2) for the FFPE DNA 
(1ng/µL) of patient M031. The third cluster of grey droplets in (b) shows unspecific wild type 
droplets that became apparent upon running the samples at 58.2oC rather than the previously 
optimized Tm for the KRAS assay (60.3












Figure 4.16. Comparison of mean (± SEM) mutant and wild type droplet concentration 
(copies/µL) detected for KRAS c.35G>A and TP53 c.818G>A single mutation (Assay 1 & 2) 
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Primer and probe concentration for both KRAS c.35G>T and TP53 c.524G>A assays were 
optimized, as shown in Table 4.7, in the FFPE DNA isolated from patient M040 for a 
multiplex ddPCR assay. The optimized multiplex assay (Figure 4.17) shows well separated 
amplitude bands and distinct clusters of mutant droplets upon increasing the primer and 
mutant probe concentration of the KRAS assay. However, since the wild type droplets were 
observed to be harder to separate, the concentration of the KRAS wild type probe were 
therefore optimized to be three times higher than that of the TP53 assay in order to obtain 
separated fluorescence bands enough to distinguish between the assays.  
 
More distinct separation between the clusters of mutant and wild type droplets as achieved 
upon running the samples at 58.2oC rather than the previously optimized Tm of 60.1
oC from 
gradient PCR. The optimized multiplex ddPCR assay for M040 was also compared to the 
corresponding single mutation assays (Figure 4.18) in order to check if the assays can 
effectively detect both the KRAS and TP53 mutation with the same accuracy. Upon analysis 
of the obtained mutant and wild type droplet concentration from the generated assays, it can 
be observed in Figure 4.19 that there is a comparable mean concentration (copies/µL ± SEM) 
detected from multiplex ddPCR and single mutation ddPCR assays. In particular, the 
multiplex ddPCR assay detected 9.98 ± 0.21 and 11.74 ± 0.76 copies/µL of the KRAS and 
TP53 mutation respectively, while the single mutation ddPCR assay detected 10.34 ± 0.35 









 Assay 1 Assay 2 Assay 3 
Mastermix 11 11 11 
KRAS Primer Forward 0.77 - 0.77 
Reverse 0.77 - 0.77 
KRAS Probe Mutant Type 0.50 - 0.50 
Wild Type 0.99 - 0.99 
TP53 Primer Forward - 0.66 0.66 
Reverse - 0.66 0.66 
TP53 Probe Mutant Type - 0.30 0.30 
Wild Type - 0.33 0.33 
Water  1.97 3.05 0.02 
Sample (M040) 6 6 6 
TOTAL 22 22 22 
Table 4.7. Volume (µL) of reagents used for KRAS c.35G>T and TP53 c.524G>A single 
mutation (Assay 1 & 2) and multiplex (Assay 3) ddPCR assays for the FFPE DNA of patient 












Multiplex ddPCR assay (Assay 3) 
(a)
(b)
Figure 4.17. 1D (a) and 2D (b) plot of droplet fluorescence detected KRAS c.35G>T and 












Single mutation ddPCR assay (Assay 1 & 2) 
(a)
(b)  
Figure 4.18. 1D (a) and 2D (b) plot of droplet fluorescence detected from KRAS c.35G>T 
and TP53 c.524G>A single mutation ddPCR assays (Assay 1 & 2) for the FFPE DNA 














Figure 4.19. Comparison of mean (± SEM) mutant and wild type droplet concentration 
(copies/µL) detected for KRAS c.35G>T and TP53 c.524G>A single mutation (Assay 1 & 2) 
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Primer and probe concentration for both BRAF c.1799T>A and TP53 c.817C>T assays were 
optimized, as shown in Table 4.8, in the FFPE DNA isolated from patient M048 for a 
multiplex ddPCR assay. The optimized multiplex assay (Figure 4.20) showed well separated 
amplitude bands and distinct clusters of mutant droplets upon increasing the primer 
concentration of the BRAF assay. However, since the mutant and wild type droplets were 
observed to be harder to separate, the concentration of the BRAF mutant type probe was 
therefore optimized to be three times higher than that of the TP53 assay, while the BRAF wild 
type probe concentration was optimized to be two times higher in order to obtain highly 
separated fluorescence bands. More distinct separation between the clusters of mutant and 
wild type droplets was achieved upon running the samples at 58.2oC rather than the 
previously optimized Tm of 60.1
oC from gradient PCR.  
 
The optimized multiplex ddPCR assay for M048 was also compared to the corresponding 
single mutation assays (Figure 4.21) in order to check if the assays can effectively detect both 
the BRAF and TP53 mutation with the same accuracy. Upon analysis of the obtained mutant 
and wild type droplet concentration from the generated assays, it can be observed in Figure 
4.22 that there is a comparable mean concentration (copies/µL ± SEM) detected from 
multiplex ddPCR and single mutation ddPCR assays. In particular, the multiplex ddPCR 
assay detected 10.94 ± 0.26 and 11.72 ± 0.45 copies/µL of the BRAF and TP53 mutation 
respectively, while the single mutation ddPCR assay detected 12.78 ± 0.19 and 10.36 ± 0.21 








 Assay 1 Assay 2 Assay 3 
Mastermix 11 11 11 
BRAF Primer Forward 0.77 - 0.77 
Reverse 0.77 - 0.77 
BRAF Probe Mutant Type 0.825 - 0.825 
Wild Type 0.55 - 0.55 
TP53 Primer Forward - 0.66 0.66 
Reverse - 0.66 0.66 
TP53 Probe Mutant Type - 0.275 0.275 
Wild Type - 0.275 0.275 
Water  2.085 3.13 0.215 
Sample (M048) 6 6 6 
TOTAL 22 22 22 
Table 4.8. Volume (µL) of reagents used for BRAF c.1799T>A and TP53 c.817C>T single 
mutation (Assay 1 & 2) and multiplex (Assay 3) ddPCR assays for the FFPE DNA of patient 













Multiplex ddPCR assay (Assay 3) 
(a)
(b)
Figure 4.20. 1D (a) and 2D (b) plot of droplet fluorescence detected from BRAF c.1799T>A 














Single mutation ddPCR assay (Assay 1 & 2) 
(a)
(b)
Figure 4.21. 1D (a) and 2D (b) plot of droplet fluorescence detected from BRAF c.1799T>A 
and TP53 c.817C>T single mutation ddPCR assays (Assay 1 & 2) for the FFPE DNA 















Figure 4.22. Comparison of mean (± SEM) mutant and wild type droplet concentration 
(copies/µL) detected for BRAF c.1799T>A and TP53 c.817C>T single mutation (Assay 1 & 
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MONITORING MULTIPLE MUTATIONS IN CTDNA 
Once the multiplex ddPCR assays were successfully optimized for each patient, the study 
then focused on the surveillance of two somatic mutation markers in the limited volumes of 
ctDNA isolated from serial plasma samples of three advanced CRC patients (M009, M019, 
and M048) with metastasis to the liver. The levels of the mutation markers in individual 
patient samples were compared with their clinical endpoints and then evaluated to see if there 
were any discordant ctDNA patterns that may possibly reflect emerging clonal heterogeneity.  
 
Results show that the optimized multiplex ddPCR assay successfully detected BRAF, KRAS 
and TP53 gene mutations in the ctDNA isolated from the serial plasma samples of these 
patients. No mutant copies were detected in the gDNA samples (wild type positive control). 
Although the levels of TP53 mutation dominated in some of the plasma cycles, very similar 
ctDNA concentration and dynamic patterns were observed for the mutation markers in the 
individual CRC patients. Moreover, the ctDNA levels detected from the multiplex ddPCR 
assays were observed to be comparable to the results acquired from the single mutation 














The previously optimized multiplex ddPCR assay was utilized for the concurrent monitoring 
of the levels of KRAS c.35G>A and TP53 c.524G>A mutation in 5 cycles of serial plasma 
samples of patient M009 collected from April to June 2017 (Figure 4.23). Results show that 
the FFPE DNA extracted from the primary tumour specimen of M009 had 381.63 ± 29.34 
copies/µL of the KRAS mutation, and 960.19 ± 55.50 copies/µL of the TP53 mutation.  
 
Analysis of the first cycle revealed the highest ctDNA concentration for both the KRAS 
(2240.93 ± 39.71 copies/mL) and TP53 (6742.04 ± 177.42 copies/mL) assay throughout the 
study. The patient then started treatment with FOLFOX6 (folinic acid, fluorouracil and 
oxaliplatin). The ctDNA immediately dropped down to lower levels in the subsequent cycles 
for both assays. However, the patient ceased blood collection and was withdrawn from the 
study in June 2017 after only 5 cycles of blood collection. The results from the ctDNA 
analysis suggest possible correlation with further CT scans which later revealed significant 











Figure 4.23. Concentration (mean copies/mL plasma ± SE) of KRAS c.35G>A and TP53 
c.524G>A mutation in the ctDNA of serial blood collection cycles from patient M009. 
Levels of KRAS and TP53 mutation detected from the ctDNA of 5 cycles of plasma samples 
from April to June 2017 were analysed and quantified using multiplex ddPCR. The mean 
mutation copies/mL plasma was calculated and plotted with the standard error (SE) as error 
bars. ctDNA was detected at high levels in all the available cycles for analysis with the 
highest peak detected in the first cycle (April 2017). CT scans revealed that M009 was 
diagnosed with disease progression throughout the study. Similar dynamic patterns were 
observed for both the KRAS (red) and TP53 (blue) mutation markers and the ctDNA levels 
detected from the multiplex ddPCR assays is comparable to the results acquired from the 








The previously optimized multiplex ddPCR assay was utilized for the concurrent monitoring 
of the levels of BRAF c.1799T>A and TP53 c.818G>A mutation in 13 cycles of serial plasma 
samples of patient M019 collected from July 2017 to June 2018 (Figure 4.24). Results show 
that the FFPE DNA extracted from the primary tumour specimen of M019 had 33.01 ± 0.73 
copies/µL of the BRAF mutation and 33.53 ± 0.34 copies/µL of the TP53 mutation.   
 
Analysis of the first cycle immediately revealed high levels of ctDNA for both the BRAF 
(447.10 ± 28.93 copies/mL) and TP53 (531.66 ± 15.31 copies/mL) assay. The patient then 
started treatment with CAPEOX (oxaliplatin and capecitabine). The ctDNA immediately 
dropped down to lower levels in the subsequent cycles for both assays until the lowest 
ctDNA concentration was observed in the cycle 5 (November 2017) sample.  
 
The patient was then diagnosed by CT scans with partial response to the treatment and the 
treatment was switched to capecitabine alone. However, the levels of ctDNA started to climb 
back up until the highest concentration was reached for both the BRAF (10554.47 ± 194.10 
copies/mL) and TP53 (24782.63 ± 367.24 copies/mL) assay in the cycle 10 collected in April 
2018. Further CT scans then revealed that the patient had progressive disease and thus, the 
treatment was then switched to FOLFIRI (folinic acid, fluorouracil, irinotecan). The ctDNA 
levels started to decrease and the patient was then withdrawn from the study in June 2018. 
The results from the ctDNA analysis suggest possible correlation with further CT scans 







Figure 4.24. Concentration (mean copies/mL plasma ± SE) of BRAF c.1799T>A and 
TP53 c.818G>A mutation in the ctDNA of serial blood collection cycles from patient 
M019. Levels of BRAF and TP53 mutation detected from the ctDNA of 13 cycles of plasma 
samples from July 2017 to June 2018 were analysed and quantified using multiplex ddPCR. 
The mean mutation copies/mL plasma was calculated and plotted with the standard error (SE) 
as error bars. ctDNA remained at high levels throughout the study with the highest peak 
detected in April 2018. Fluctuations in the concentration of ctDNA detected from both BRAF 
and TP53 markers suggest potential correlation with the disease burden in all the available 
cycles for analysis. The patient was treated with FOLFIRI with partial response and then 
ceased blood collection in June 2018. Similar dynamic patterns were observed for both the 
BRAF (red) and TP53 (blue) mutation markers and the ctDNA levels detected from the 
multiplex ddPCR assays is comparable to the results acquired from the previous single 








The previously optimized multiplex ddPCR assay was utilized for the concurrent monitoring 
of the levels of BRAF c.1799T>A and TP53 c.817C>T mutation in 5 cycles of serial plasma 
samples of patient M048 collected from May to October 2018 (Figure 4.25). Results show 
that the FFPE DNA had 403.37 ± 20.59 copies/µL of the BRAF mutation and 391.40 ± 11.06 
copies/µL of the TP53 mutation.   
 
Relatively low levels of ctDNA for both the BRAF (30.23 ± 6.55 copies/mL) and TP53 
(28.66 ± 5.02 copies/mL) assay were detected in the first cycle of serial plasma samples 
collected in May 2018. The patient is then treated with CAPEOX but was later diagnosed by 
CT scans with disease progression. This suggests possible correlation with the results of the 
study which reveals an increase in the ctDNA levels in the following cycle collected in July 
2018 for both the BRAF (149.66 ± 9.88 copies/mL) and TP53 (184.71 ± 5.78 copies/mL) 
mutation markers. 
 
The levels of ctDNA continuously increased until the highest concentration for both markers 
(BRAF: 1758.03 ± 35.88 and TP53: 2162.22 ± 30.05 copies/mL) was reached in cycle 3 of 
serial plasma samples collected in August 2018. The patient was thereby treated with 
FOLFIRI and the levels of ctDNA immediately dropped down to lower levels in the 
subsequent cycles for both assays. However, the patient ceased blood collection and was 
withdrawn from the study in October 2018 after only 5 cycles of blood collection. The results 
from the ctDNA analysis suggest possible correlation with further CT scans which later 







Figure 4.25. Concentration (mean copies/mL plasma ± SE) of BRAF c.1799T>A and 
TP53 c.817C>T mutation in the ctDNA of serial blood collection cycles from patient 
M048. Levels of BRAF and TP53 mutation detected from the ctDNA of 5 cycles of plasma 
samples from May to October 2018 were analysed and quantified using multiplex ddPCR. 
The mean mutation copies/mL plasma was calculated and plotted with the standard error (SE) 
as error bars. ctDNA was detected at high levels in all the available cycles for analysis with 
the highest peak detected in the third cycle (August 2018). The results suggest potential 
correlation with CT scans which revealed that M048 was diagnosed with disease progression 
throughout the study. Similar dynamic patterns were observed for both the BRAF (red) and 
TP53 (blue) mutation markers and the ctDNA levels detected from the multiplex ddPCR 








CHAPTER 6: DISCUSSION 
 
ctDNA is the extracellular DNA released into the bloodstream that can be analysed through 
the detection of tumour-specific mutations. Determining the levels of ctDNA in the serial 
plasma samples of cancer patients undergoing several cycles of chemotherapy may 
potentially be utilised to assess the patients‟ condition (Calapre et al., 2017; Li et al., 2019). 
In this study, the dynamic serial changes in ctDNA were observed to correlate with disease 
burden of patients, response to administered treatments and overall clinical outcome 
(stable/progressive disease/tumour recurrence). Higher levels of ctDNA were mostly 
observed in patients with metastasis to the liver compared to those with metastases to lymph 
nodes, lungs and bones. Patients with higher levels or an increase in the concentration of 
ctDNA were mostly observed to have progressive disease and those with low levels of 
ctDNA were observed to likely have a low burden of metastatic disease or were eventually 
diagnosed to have stable disease during the course of study. Patients with undetectable 
ctDNA were observed to have no evidence of disease progression throughout serial plasma 
sample collection.  
 
Results also suggest that ctDNA detection in metastatic breast cancer preceded the clinical 
diagnosis of disease progression and also provided an assessment of stable disease or positive 
response to administered treatments potentially earlier than scheduled CT imaging. However, 
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it must be noted that CT scans are only often done every six to 12 months for patients with a 
high risk of recurrence (Follow-up care for colorectal cancer, 2013) and the observed lead 
time of ctDNA analysis may only be possibly caused by the delayed radiographical tests 
scheduled for a number of cancer patients due to the difficult or limited access to health 
facilities. The lead time is most likely due to the easier access to blood sample collection and 
this delay must not be directly correlated with the efficiency of the CT scans.  
 
This highlights the importance of potentially implementing liquid biopsies utilizing ctDNA 
into standard cancer follow-up procedures in the future for monitoring disease burden and 
patient prognosis. However, finding effective treatments to target this malignancy still 
remains challenging mainly due to the heterogeneity of metastatic cancers that are known to 
continuously evolve and acquire multiple driver mutations that may not be present in the 
primary tumour (Smith et al., 2019; Feng et al., 2018). Since the target mutation marker 
remained the same throughout the analysis; it is yet to be determined from our results 
whether ctDNA has accurately correlated the overall tumour burden, or there are other factors 
that must also be considered. Based on the results, fluctuations in the levels of ctDNA were 
constantly seen in patients over time, but it is unknown whether the lower levels of ctDNA 
simply reflected a lower disease burden due to a decrease in the overall size of the tumour or 
there have only been a diminished release of ctDNA in the patients‟ samples due to a lower 
tumour activity. Thus, the surveillance of a single mutation marker is unlikely to be sufficient 
to comprehensively evaluate the disease burden.  
 
In order to provide a significant improvement in the ctDNA analysis, this study also explored 
the identification and detection of multiple tumour-specific mutations in the ctDNA of two 
metastatic breast cancer patients (BRC004 and BRC095) and three CRC patients (M009, 
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M019, and M048). Results show that the multiplex ddPCR assays successfully detected 
KRAS, TP53, PIK3CA, BRCA2 and BRAF gene mutations. Although different concentrations 
of ctDNA were detected and levels of certain mutations dominated in some plasma cycles, 
very similar dynamic patterns were observed for both mutation markers identified for each 
breast and colorectal cancer patient. Moreover, the overall ctDNA levels detected from the 
multiplex ddPCR assays is comparable to the results acquired from the single mutation 
ddPCR assay.  
 
However, as good as the current progress is in the method development, simultaneously 
monitoring two tumour-specific mutations using our novel ddPCR multiplexing method may 
still not be sufficient to comprehensively monitor the clonal heterogeneity. It is likely that 
new drug resistant clones will continue to emerge throughout the course of the disease and 
our current established method may still require further improvements. The number of 
variants that could be detected in the multiplex assays may be increased by instead utilizing 
the new ddPCR™ Multiplex Supermix [Bio-Rad, USA]. Since this supermix is more 
concentrated (4x) than the one utilized in the current protocol, this would possibly allow for 
the detection of more than just two variants combined in a multiplex assay. In addition to 
regular physical examinations and CT scans, the current established protocol can be further 
improved by developing routinely scheduled ctDNA surveillance in the first five years after 
treatment when the risk of recurrence is highest (Follow-up care for breast cancer, 2015; 
Follow-up care for colorectal cancer, 2013). Moreover, based on the pattern of recurrence in 
both cancers, it is also recommended that routine sequencing the plasma samples be done 
every three to six months, especially for the first few years of treatment, to ensure that the 




Overall, this data suggests that monitoring the levels of ctDNA at each chemotherapy cycle 
may help determine the effectiveness of treatments and prognosis of metastatic breast and 
CRC cancer patients. To minimise the adverse reactions of therapies, ctDNA could be 
utilised to evaluate the lowest possible treatment dosage that can be given in patients. Most 
importantly, by identifying the emergence of drug resistance in the tumour at the earliest 
moment, this approach allows for prompt termination of futile treatments and faster initia tion 
of next-in line therapies (Olsson et al., 2015; Popper, 2016).  
 
CHAPTER 7: CONCLUSION 
The results presented in this study have contributed to the establishment of the highly 
sensitive multiplex ddPCR analysis of ctDNA in serial blood samples as a possible cancer 
surveillance tool. Future research is however required to better develop the ctDNA analysis 
pipeline for metastatic breast cancer patients with DNA samples that failed to have any 
mutations identified with Targeted NGS. Bioinformatics tools, such as Genome Analysis 
Toolkit (GATK 3.4.0), VarScan2, UMI-tools, and MAGERI, may be used to detect and 
distinguish somatic mutations from germline variants for a more efficient and standardized 
marker identification protocol (Huang et al., 2019; Shu et al., 2017). The sequencing data can 
further be analysed to develop a smaller custom gene panel with only the clinically relevant 
targets to increase sensitivity for finding the most robust biomarkers used for ctDNA 
analysis. Routine sequencing of the subsequent plasma samples from patients undergoing 
treatment cycles can also be explored. We also propose that more cancer patients are 
monitored with multiplex assays to further explore possible tumour heterogeneity arising in 
the course of the disease. Finally, the potential utility of ctDNA for the detection of early-
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0.2 mL 8 well PCR Tube Strip - 4titude, England 
1.7 mL microfuge tube - SorensonTM BioScience, Inc. USA 
10 mL Strippets - Griener Bio-one, Austria 
15 mL Centrifuge Tubes - Griener Bio-one, Austria 
50 mL Centrifuge Tubes - Griener Bio-one, Austria 
96 well plates - Bio-Rad Laboratories, USA 
C1000 Touch™ Thermal Cycler (96 Deep-well Reaction) - Bio-Rad Laboratories, USA 
Cell Free DNA BCTs - Streck, USA 
Cell Free DNA Blood Collection Tubes - Roche, Switzerland 
Contherm Thermotec 2000 Oven - Contherm Scientific Ltd, New Zealand 
DG32TM Cartridges for AutoDG - Bio-Rad Laboratories, USA 
Eppendorf Centrifuge 5417C - Eppendorf, Germany 
Eppendorf Centrifuge 5810R - Eppendorf, Germany 
Fume Cupboard 326h - Thermoplastic Engineering Ltd, New Zealand 
Glass Cover Slips - Esco Optics Inc, USA 
Leica HI1210 Water Bath – Bio-Strategy, New Zealand 
Leica RM 2125RT Sectioner – Bio-Stratergy, New Zealand 
Microscope Slides HistoBand (Adhesion of Tissue Sections) - Marienfeld, Germany 
MicroTUBE AFA Fibre Snap-Cap - Covaris, USA 
MicroTUBE-15 AFA Beads - Covaris, USA 
MiSeq System - Illumina, USA 
Olympus DP71 camera - Olympus, Japan 
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Olympus Inverted Microscope IX71 - Olympus, Japan 
Olympus Microscope BX51 - Olympus, Japan 
Pierceable Foil Heat Seals - Bio-Rad Laboratories, USA 
PX1™ PCR Plate Sealer - Bio-Rad Laboratories, USA 
QX200 AutoDG ™ Droplet Digitial ™ PCR System – Bio-Rad Laboratories, USA 
QX200 Droplet Reader ™- Bio-Rad Laboratories, USA 
S220 Focused-ultrasonicator - Covaris, USA 
Serological Pipetter - Biolab Scientific Ltd, Canada 
 
Reagents 
Automated Droplet Generator Oil for Probes - Bio-Rad Laboratories, USA 
ddPCR TM Supermixes for Probes (No dUTPs) - Bio-Rad Laboratories, USA 
ddPCR ™ Droplet Reader Oil - Bio-Rad Laboratories, USA 
DPX Mountant for Histology - Sigma Aldrich, USA 
Eosin Y Solution - Sigma Aldrich, USA 
Ethanol (Absolute) - Lab Supplies, New Zealand 
Ethanol (Analytic Grade) - Lab Supplies, New Zealand 
Human Genomic DNA - Roche, Switzerland 
Isopropanol - Lab Supplies, New Zealand 
Mayer's Haematoxylin Solution - Sigma Aldrich, USA 
UltraPure TM DNase/RNase Free Distilled Water - Thermo Fisher Scientific, USA 
Xylene - Scharlau Chemicals, Spain 
 
Commercial Kits 
GeneRead FFPE DNA Kit - Qiagen, Germany 
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High Sensitivity DNA Analysis Kit - Agilent Technologies, USA 
MiSeq Reagents Kit v2 – Illumina, USA 
Multiplex I cfDNA Reference Standard Set - Horizon, England 
QIAmp Circulating Nucleic Acid Kit - Qiagen, Germany 
QIASeq Targeted DNA Panels (Human Breast Cancer Panel) - Qiagen, Germany 
QubitTM dsDNA High Sensitivity Kit - Thermo Fisher Scientific, USA 
SureSelectXT Reagent Kit- Agilent Technologies, USA 
ThruPLEX ® Tag-Seq Kit - Rubicon Genomics, USA 
 
Software 
QuantaSoftTM Software - Bio-Rad Laboratories, USA 
QuantaSoftTM Analysis Pro Software - Bio-Rad Laboratories, USA 
 
Web Portals 
NCBI PrimerBLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) 
Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) 
Varsome: The Human Genomics Community (https://varsome.com/) 
Catalogue of Somatic Mutations in Cancer [COSMIC] (https://cancer.sanger.ac.uk/cosmic) 
Bio-Rad Droplet DigitalTM PCR Assays - Mutation Detection 
(https://www.biorad.com/digital-assays/#/assays-create/mutation) 
Illumina BaseSpace Sequence Hub (https://basespace.illumina.com/) 
Qiagen QIAseq DNA Enrichment (https://ngsdataanalysis.qiagen.com/QIAseqDNA/) 






QUBIT CONCENTRATION OF DNA SAMPLES UPON EXTRACTION 
Table S1. Qubit concentration (ng/µL) of FFPE DNA from BRC patients‟ tissue blocks 
HOSPITAL ID STUDY ID FFPE CONC  (ng/µL) 
GMR011 BRC090 27.70 
TJD012 BRC091 6.370 
SMJ013 BRC092 40.60 
KJM010 BRC049 8.240 
ACH006 BRC013 20.70 
DMN009 BRC050 51.00 
ACH008 BRC052 9.750 
JMG014 BRC089 16.60 
NMT008 BRC048 50.00 
LNL001 BRC001 37.10 
ACH003 BRC004 30.20 
DC003 BRC005 49.30 
CDF002 BRC007 26.50 
ACH004 BRC008 47.40 
RMB006 BRC009 14.40 
GFW016 BRC088 5.370 
ACH008 BRC052 16.70 
ACH005 BRC012 49.80 
PSR018 BRC102 22.30 
ACH014 BRC099 56.00 
ACH009 BRC053 27.80 
ACH015 BRC100 45.10 
ACH002 BRC003 8.310 
ACH011 BRC094 12.90 
ACH016 BRC101 7.450 
ACH012 BRC095 3.920 






Table S2. Qubit concentration (ng/µL) of gDNA from buffy coat of BRC patients‟ samples 
HOSPITAL ID STUDY ID gDNA CONC (ng/µL) 
ACH007 BRC051 0.105 
ACH009 BRC053 1.070 
ACH010 BRC093 16.50 
ACH011 BRC094 12.90 
ACH012 BRC095 4.640 
ACH014 BRC099 17.40 
ACH015 BRC100 37.70 
ACH016 BRC101 41.50 
I-L017 BRC097 33.40 




Table S3. Qubit concentration (ng/µL) of FFPE DNA from CRC patients‟ tissue blocks 





































Figure S2. Fragment analyzer results for DNA Fragmentation to ~200bp before the library 






























PRIMER AND PROBE DESIGN 
TP53  
c.560-1G>A 
Forward Primer GCCTCTGATTCCTCACTGAT 59.0 °C 
Reverse Primer TCCACTCGGATAAGATGCTG 59.1 °C 
Mutant Type Probe TCTTAAGTCTGGCCCCTCC 60.3 °C 







WILD TYPE PROBE 
 







PIK3CA c.1624G>A Forward Primer CTCAAAGCAATTTCTACACG 55.1 
Reverse Primer TTACCTGTGACTCCATAGAA 55.0 
Mutant Type Probe CCTCTCTCTAAAATCACTGAGC 58.3 







WILD TYPE PROBE 
 
















WILD TYPE PROBE 
 





ESR1 c.1636G>A Forward Primer GTACAGCATGAAGTGCAAGA 58.3 °C 
 Reverse Primer TAGTGGGCGCATGTAGG 58.0 °C 
 Mutant Type Probe AGATGCTGGACACCCACC 61.2 °C 
 Wild Type Probe AGATGCTGGACGCCCACC 61.6 °C 
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PIK3CA c.3140A>G Forward Primer ATAAAACTGAGCAAGAGGCT 56.9 °C 
 Reverse Primer GTGTGGAAGATCCAATCCAT 57.4 °C 
 Mutant Type Probe TGAATGATGCACGTCATGGT 60.2 °C 






WILD TYPE PROBE 
 











WILD TYPE PROBE 
 




TP53 c.584T>C Forward Primer CTGATTGCTCTTAGGTCTG 54.7 °C 
 Reverse Primer TTCTGTCATCCAAATACTCC 54.5 °C 
 Mutant Type Probe CAGCATCTTACCCGAGTG 57.0 °C 










WILD TYPE PROBE 
 




TP53 c.636delT Forward Primer AGTTGCAAACCAGACCTC 57.0 °C 
 Reverse Primer TGTGGAGTATTTGGATGACA 56.2 °C 
 Mutant Type Probe CCACACTATGTCGAAAGTGTT 58.5 °C 




GRADIENT DDPCR RESULTS OF MUTATION ASSAYS 
 
PATIENT BRC004 [PIK3CA c.1624G>A] 
 










PATIENT BRC008 [ESR1 c.1636G>A] 
 













PATIENT BRC009 [ZBED4 c.1094C>T] 
 












PATIENT BRC013 [TP53 c.560-1G>A] 
 











PATIENT BRC050 [TP53 c. 939delA] 
 













PATIENT BRC090 [PIK3CA c.3140A>G] 
 














PATIENT BRC092 [TP53 c.584T>C] 
 














Figure S11. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 







Figure S12. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 












Figure S13. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 












Figure S14. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 








Figure S15. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 







Figure S16. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 






Figure S17. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 






Figure S18. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 










Figure S19. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 















Figure S20. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 













Figure S21. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 













Figure S22. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 










Figure S23. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 









Figure S24. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 








Figure S25. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 









Figure S25. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 










Figure S26. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 
KRAS c.35G>A and TP53 c.524G>A mutation in serial plasma samples of Patient M009 










Figure S27. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 
BRAF c.1799T>A and TP53 c.818G>A mutation in serial plasma samples of Patient M019 










Figure S27. 1D and 2D plot of droplet fluorescence amplitude obtained upon the detection of 
BRAF c.1799T>A and TP53 c.817C>T mutation in serial plasma samples of Patient M048 
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